



(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
18.11.2020 Bulletin 2020/47

(21) Application number: **20178708.2**

(22) Date of filing: **27.09.2013**

(51) Int Cl.:
C07K 14/015 (2006.01) **C12N 15/86** (2006.01)
C12N 15/35 (2006.01) **C12N 15/63** (2006.01)
C12N 15/19 (2006.01) **C12N 15/09** (2006.01)
C12N 7/00 (2006.01) **C12N 5/10** (2006.01)
A61K 48/00 (2006.01) **A61K 35/76** (2015.01)
A61P 25/00 (2006.01)

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: **28.09.2012 US 201261707108 P**

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
13841643.3 / 2 900 686

(71) Applicant: **The University of North Carolina at Chapel Hill**
Chapel Hill, NC 27599-4105 (US)

(72) Inventors:
• **MCCOWN, Thomas**
Carrboro, NC 27510 (US)
• **GRAY, Steven**
Southlake, TX 76092 (US)

(74) Representative: **Kransell & Wennborg KB**
P.O. Box 27834
115 93 Stockholm (SE)

Remarks:
This application was filed on 08.06.2020 as a divisional application to the application mentioned under INID code 62.

(54) **AAV VECTORS TARGETED TO OLIGODENDROCYTES**

(57) The invention relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.




FIG. 1

Description**Background**

[0001] Adeno-associated virus (AAV) was first reported to efficiently transduce muscle over ten years ago (Xiao et al., (1996) J. Virol. 70:8098-8108). The recombinant AAV (rAAV) genome composed of a foreign expression cassette and AAV inverted terminal repeat (ITR) sequences exists in eukaryotic cells in an episomal form that is responsible for persistent transgene expression (Schnepp et al., (2003) J. Virol. 77:3495-3504). AAV vectors have a good safety profile. No human disease has been associated with wild-type AAV infection and low toxicity is observed in human subjects following transduction by rAAV (Manno et al., (2003) Blood 101:2963-2972).

[0002] In the brain, the vast majority of AAV vectors exhibit a dominant preference for neurons with a very low efficacy for other cell types, such as oligodendrocytes. Recent advances in AAV engineering and directed evolution have expanded the ability to develop novel AAV serotypes, including vectors with altered tropism (Gray et al., (2010) Mol. Ther. 18:570-578). However, in the central nervous system, all AAV vectors and chimeras, except AAV4, exhibit a dominant neuronal tropism. AAV vectors that efficiently target oligodendrocytes have not been developed.

Summary

[0003] The present invention is based, in part, on the development of a chimeric AAV capsid sequence that exhibits a dominant tropism for oligodendrocytes. The chimeric capsid can be used to create AAV vectors that transduce oligodendrocytes in the central nervous system (CNS) of subjects.

[0004] Thus, one aspect of the invention relates to a nucleic acid encoding an AAV capsid, the nucleic acid comprising an AAV capsid coding sequence that is at least 90% identical to: (a) the nucleotide sequence of SEQ ID NO:1; or (b) a nucleotide sequence encoding any one of SEQ ID NOS:2-4, along with cells and viral particles comprising the nucleic acid.

[0005] Another aspect of the invention relates to an AAV capsid comprising an amino acid sequence at least 96% identical to any one of SEQ ID NOS:2-4, along with AAV particles comprising an AAV vector genome and the AAV capsid of the invention.

[0006] A further aspect of the invention relates to a method of producing a recombinant AAV particle comprising an AAV capsid, the method comprising: providing a cell *in vitro* with a nucleic acid of the invention, an AAV rep coding sequence, an AAV vector genome comprising a heterologous nucleic acid, and helper functions for generating a productive AAV infection; and allowing assembly of the recombinant AAV particle comprising the AAV capsid and encapsidating the AAV vector genome.

[0007] An additional aspect of the invention relates to a pharmaceutical formulation comprising the nucleic acid, virus particle, AAV capsid, or AAV particle of the invention in a pharmaceutically acceptable carrier.

[0008] Another aspect of the invention relates to a method of delivering a nucleic acid of interest to an oligodendrocyte, the method comprising contacting the oligodendrocyte with the AAV particle of the invention.

[0009] A further aspect of the invention relates to a method of delivering a nucleic acid of interest to an oligodendrocyte in a mammalian subject, the method comprising administering an effective amount of the AAV particle or pharmaceutical formulation of the invention to a mammalian subject.

[0010] An additional aspect of the invention relates to a method of delivering a nucleic acid of interest to an area of the CNS bordering a compromised blood brain barrier area in a mammalian subject, the method comprising intravenously administering an effective amount of the AAV particle or pharmaceutical formulation of the invention to a mammalian subject.

[0011] Another aspect of the invention relates to a method of treating a disorder associated with oligodendrocyte dysfunction in a mammalian subject in need thereof, the method comprising administering a therapeutically effective amount of the AAV particle or pharmaceutical formulation of the invention to a mammalian subject.

[0012] A further aspect of the invention relates to a method of preparing an AAV capsid having a tropism profile of interest, the method comprising modifying the AAV capsid of the invention to insert an amino acid sequence providing the tropism profile of interest.

[0013] These and other aspects of the invention are set forth in more detail in the description of the invention below.

Brief Description of the Drawings**[0014]**

Fig. 1 shows the chimeric structure of the BNP61, BNP62, and BNP63 AAV capsid clones.

Figs. 2A-2C show the tropism of BNP61 for oligodendrocytes in rat caudate. (A) shows GFP positive oligodendrocytes in the rat caudate 1 week after the infusion of BNP61-CBh-GFP vectors. Note that there are no GFP positive neurons.

(B) shows a higher magnification that reflects clear oligodendrocyte morphology, and (C) shows that none of the GFP positive cells colocalize with the cellular marker for astrocytes, GFAP(red).

Figs. 3A-3B show the tropism of BNP61 for oligodendrocytes in primary oligodendrocyte cultures.

Fig. 4 shows the biodistribution of BNP61 (MG001) and parent capsids after intravenous injection in female wild-type mice, determined by quantitative PCR. The Y-axis is copies of GFP per diploid mouse genome.

Fig. 5 shows that BNP61 crosses the compromised blood-brain barrier after peripheral administration.

Fig. 6 shows the tropism of BNP63 for oligodendrocytes in rat piriform cortex.

Detailed Description

[0015] The present invention is based, in part, on the development of a chimeric AAV capsid sequence that exhibits a tropism for oligodendrocytes. The chimeric capsid can be used to create AAV vectors that transduce oligodendrocytes in the CNS of subjects.

[0016] The present invention is explained in greater detail below. This description is not intended to be a detailed catalog of all the different ways in which the invention may be implemented, or all the features that may be added to the instant invention. For example, features illustrated with respect to one embodiment may be incorporated into other embodiments, and features illustrated with respect to a particular embodiment may be deleted from that embodiment. In addition, numerous variations and additions to the various embodiments suggested herein will be apparent to those skilled in the art in light of the instant disclosure which do not depart from the instant invention. Hence, the following specification is intended to illustrate some particular embodiments of the invention, and not to exhaustively specify all permutations, combinations and variations thereof.

[0017] Unless the context indicates otherwise, it is specifically intended that the various features of the invention described herein can be used in any combination. Moreover, the present invention also contemplates that in some embodiments of the invention, any feature or combination of features set forth herein can be excluded or omitted. To illustrate, if the specification states that a complex comprises components A, B and C, it is specifically intended that any of A, B or C, or a combination thereof, can be omitted and disclaimed singularly or in any combination.

[0018] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.

[0019] Nucleotide sequences are presented herein by single strand only, in the 5' to 3' direction, from left to right, unless specifically indicated otherwise. Nucleotides and amino acids are represented herein in the manner recommended by the IUPAC-IUB Biochemical Nomenclature Commission, or (for amino acids) by either the one-letter code, or the three letter code, both in accordance with 37 C.F.R. §1.822 and established usage.

[0020] Except as otherwise indicated, standard methods known to those skilled in the art may be used for production of recombinant and synthetic polypeptides, antibodies or antigen-binding fragments thereof, manipulation of nucleic acid sequences, production of transformed cells, the construction of rAAV constructs, modified capsid proteins, packaging vectors expressing the AAV rep and/or cap sequences, and transiently and stably transfected packaging cells. Such techniques are known to those skilled in the art. See, e.g., SAMBROOK et al., MOLECULAR CLONING: A LABORATORY MANUAL 2nd Ed. (Cold Spring Harbor, NY, 1989); F. M. AUSUBEL et al. CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (Green Publishing Associates, Inc. and John Wiley & Sons, Inc., New York).

I. Definitions.

[0021] The designation of all amino acid positions in the AAV capsid subunits in the description of the invention and the appended claims is with respect to VP1 capsid subunit numbering.

[0022] As used in the description of the invention and the appended claims, the singular forms "a," "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0023] As used herein, "and/or" refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative ("or").

[0024] Moreover, the present invention also contemplates that in some embodiments of the invention, any feature or combination of features set forth herein can be excluded or omitted.

[0025] Furthermore, the term "about," as used herein when referring to a measurable value such as an amount of a compound or agent of this invention, dose, time, temperature, and the like, is meant to encompass variations of $\pm 20\%$, $\pm 10\%$, $\pm 5\%$, $\pm 1\%$, $\pm 0.5\%$, or even $\pm 0.1\%$ of the specified amount.

[0026] The term "consisting essentially of" as used herein in connection with a nucleic acid, protein or capsid structure means that the nucleic acid, protein or capsid structure does not contain any element other than the recited element(s) that significantly alters (e.g., more than about 1%, 5% or 10%) the function of interest of the nucleic acid, protein or

capsid structure, e.g., tropism profile of the protein or capsid or a protein or capsid encoded by the nucleic acid.

[0027] The term "adeno-associated virus" (AAV) in the context of the present invention includes without limitation AAV type 1, AAV type 2, AAV type 3 (including types 3A and 3B), AAV type 4, AAV type 5, AAV type 6, AAV type 7, AAV type 8, AAV type 9, AAV type 10, AAV type 11, avian AAV, bovine AAV, canine AAV, equine AAV, and ovine AAV and any other AAV now known or later discovered. See, e.g., BERNARD N. FIELDS et al., VIROLOGY, volume 2, chapter 69 (4th ed., Lippincott-Raven Publishers). A number of additional AAV serotypes and clades have been identified (see, e.g., Gao et al., (2004) J. Virol. 78:6381-6388 and **Table 1**), which are also encompassed by the term "AAV."

[0028] The genomic sequences of various AAV and autonomous parvoviruses, as well as the sequences of the ITRs, Rep proteins, and capsid subunits are known in the art. Such sequences may be found in the literature or in public databases such as the GenBank® database. See, e.g., GenBank® Accession Numbers NC 002077, NC 001401, NC 001729, NC 001863, NC 001829, NC 001862, NC 000883, NC 001701, NC 001510, AF063497, U89790, AF043303, AF028705, AF028704, J02275, J01901, J02275, X01457, AF288061, AH009962, AY028226, AY028223, NC 001358, NC 001540, AF513851, AF513852, AY530579, AY631965, AY631966. See also, e.g., Srivastava et al., (1983) J. Virol. 45:555; Chiorini et al., (1998) J. Virol. 71:6823; Chiorini et al., (1999) J. Virol. 73:1309; Bantel-Schaal et al., (1999) J. Virol. 73:939; Xiao et al., (1999) J. Virol. 73:3994; Muramatsu et al., (1996) Virology 221:208; Shade et al., (1986) J. Virol. 58:921; Gao et al., (2002) Proc. Nat. Acad. Sci. USA 99:11854; international patent publications WO 00/28061, WO 99/61601, WO 98/11244; U.S. Patent No. 6,156,303. See also **Table 1**. An early description of the AAV1, AAV2 and AAV3 terminal repeat sequences is provided by Xiao, X., (1996), "Characterization of Adeno- associated virus (AAV) DNA replication and integration," Ph.D. Dissertation, University of Pittsburgh, Pittsburgh, PA.

Table 1

	GenBank Accession Number			GenBank Accession Number			GenBank Accession Number
Complete Genomes			Hu T88	AY695375		Hu42	AY530605
Adeno- associated virus 1	NC_ 002077,AF063497		Hu T71	AY695374		Hu67	AY530627
Adeno- associated virus 2	NC_001401		Hu T70	AY695373		Hu40	AY530603
Adeno- associated virus 3	NC_001729		Hu T40	AY695372		Hu41	AY530604
Adeno- associated virus 3B	NC_001863		Hu T32	AY695371		Hu37	AY530600
Adeno- associated virus 4	NC_001829		Hu T17	AY695370		Rh40	AY530559
Adeno- associated virus 5	Y18065, AF085716		Hu LG15	AY695377		Rh2	AY243007
Adeno- associated virus 6	NC_001862		Clade C			Bb1	AY243023
Avian AAV ATCC VR-865	AY186198, AY629583, NC_ 004828		Hu9	AY530629		Bb2	AY243022
Avian AAV strain DA-1	NC_006263, AY629583		Hu10	AY530576		Rh10	AY243015

EP 3 738 974 A1

(continued)

		GenBank Accession Number			GenBank Accession Number			GenBank Accession Number
5	Complete Genomes			Hu T88	AY695375		Hu42	AY530605
10	Bovine AAV	NC_005889, AY388617		Hu11	AY530577		Hu17	AY530582
	Clade A			Hu53	AY530615		Hu6	AY530621
	AAV1	NC_ 002077,AF063497		Hu55	AY530617		Rh25	AY530557
15	AAV6	NC_001862		Hu54	AY530616		Pi2	AY530554
	Hu.48	AY530611		Hu7	AY530628		Pi1	AY530553
	Hu 43	A Y530606		Hu18	AY530583		Pi3	AY530555
20	Hu 44	AY530607		Hu15	AY530580		Rh57	AY530569
	Hu 46	A Y530609		Hu16	AY530581		Rh50	AY530563
	Clade B			Hu25	AY530591		Rh49	AY530562
	Hu. 19	A Y530584		Hu60	AY530622		Hu39	AY530601
25	Hu. 20	A Y530586		Ch5	AY243021		Rh58	AY530570
	Hu 23	A Y530589		Hu3	AY530595		Rh61	AY530572
	Hu22	AY530588		Hu1	AY530575		Rh52	AY530565
30	Hu24	AY530590		Hu4	AY530602		Rh53	AY530566
	Hu21	AY530587		Hu2	AY530585		Rh51	AY530564
	Hu27	AY530592		Hu61	AY530623		Rh64	AY530574
35	Hu28	AY530593		Clade D			Rh43	AY530560
	Hu 29	AY530594		Rh62	AY530573		AAV8	AF513852
	Hu63	AY530624		Rh48	AY530561		Rh8	AY242997
	Hu64	AY530625		Rh54	AY530567		Rh1	AY530556
40	Hu13	AY530578		Rh55	AY530568		Clade F	
	Hu56	AY530618		Cy2	AY243020		Hu14 (AAV9)	AY530579
45	Hu57	AY530619		AAV7	AF513851		Hu31	AY530596
	Hu49	AY530612		Rh35	AY243000		Hu32	AY530597
	Hu58	AY530620		Rh37	AY242998		Clonal Isolate	
50	Hu34	AY530598		Rh36	AY242999		AAV5	Y18065, AF085716
	Hu35	AY530599		Cy6	AY243016		AAV 3	NC_001729
	AAV2	NC_001401		Cy4	AY243018		AAV3B	NC_001863
55	Hu45	AY530608		Cy3	AY243019		AAV4	NC_001829
	Hu47	AY530610		Cy5	AY243017		Rh34	AY243001
	Hu51	AY530613		Rh13	AY243013		Rh33	AY243002

(continued)

	GenBank Accession Number			GenBank Accession Number			GenBank Accession Number
Complete Genomes			Hu T88	AY695375		Hu42	AY530605
Hu52	AY530614		Clade E			Rh32	AY243003
Hu T41	AY695378		Rh38	AY530558			
Hu S17	AY695376		Hu66	AY530626			

[0029] A "chimeric" AAV nucleic acid capsid coding sequence or AAV capsid protein is one that combines portions of two or more capsid sequences. A "chimeric" AAV virion or particle comprises a chimeric AAV capsid protein.

[0030] The term "tropism" as used herein refers to preferential entry of the virus into certain cell or tissue type(s) and/or preferential interaction with the cell surface that facilitates entry into certain cell or tissue types, optionally and preferably followed by expression (e.g., transcription and, optionally, translation) of sequences carried by the viral genome in the cell, e.g., for a recombinant virus, expression of the heterologous nucleotide sequence(s). Those skilled in the art will appreciate that transcription of a heterologous nucleic acid sequence from the viral genome may not be initiated in the absence of trans-acting factors, e.g., for an inducible promoter or otherwise regulated nucleic acid sequence. In the case of a rAAV genome, gene expression from the viral genome may be from a stably integrated provirus and/or from a non-integrated episome, as well as any other form which the virus nucleic acid may take within the cell.

[0031] The term "tropism profile" refers to the pattern of transduction of one or more target cells, tissues and/or organs. Representative examples of chimeric AAV capsids have a tropism profile characterized by efficient transduction of oligodendrocytes with only low transduction of neurons, astrocytes, and other CNS cells.

[0032] The term "specific for oligodendrocytes" as used herein refers to a viral vector that, when administered directly into the CNS, preferentially transduces oligodendrocytes over neurons, astrocytes, and other CNS cell types. In some embodiments, at least about 80% of the transduced cells are oligodendrocytes, e.g., at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% or more oligodendrocytes.

[0033] The term "disorder associated with oligodendrocyte dysfunction" as used herein refers to a disease, disorder, or injury in which oligodendrocytes are damaged, lost, or function improperly. The term includes diseases, disorders, and injuries in which oligodendrocytes are directly affected as well as diseases, disorders, and injuries in which oligodendrocytes become dysfunctional secondary to damage to other cells (e.g., spinal cord injury).

[0034] The term "bordering a compromised blood-brain barrier area" as used herein refers to CNS cells that are adjacent to a portion of the blood-brain barrier in which the barrier function has been compromised.

[0035] As used herein, "transduction" of a cell by a virus vector (e.g., an AAV vector) means entry of the vector into the cell and transfer of genetic material into the cell by the incorporation of nucleic acid into the virus vector and subsequent transfer into the cell via the virus vector.

[0036] Unless indicated otherwise, "efficient transduction" or "efficient tropism," or similar terms, can be determined by reference to a suitable positive or negative control (e.g., at least about 50%, 60%, 70%, 80%, 85%, 90%, 95% or more of the transduction or tropism, respectively, of a positive control or at least about 110%, 120%, 150%, 200%, 300%, 500%, 1000% or more of the transduction or tropism, respectively, of a negative control).

[0037] Similarly, it can be determined if a virus "does not efficiently transduce" or "does not have efficient tropism" for a target tissue, or similar terms, by reference to a suitable control. In particular embodiments, the virus vector does not efficiently transduce (i.e., does not have efficient tropism) for liver, kidney, gonads and/or germ cells. In particular embodiments, undesirable transduction of tissue(s) (e.g., liver) is 20% or less, 10% or less, 5% or less, 1% or less, 0.1% or less of the level of transduction of the desired target tissue(s) (e.g., skeletal muscle, diaphragm muscle and/or cardiac muscle).

[0038] As used herein, the term "polypeptide" encompasses both peptides and proteins, unless indicated otherwise.

[0039] A "nucleic acid" or "nucleotide sequence" is a sequence of nucleotide bases, and may be RNA, DNA or DNA-RNA hybrid sequences (including both naturally occurring and non-naturally occurring nucleotide), but is preferably either single or double stranded DNA sequences.

[0040] As used herein, an "isolated" nucleic acid or nucleotide sequence (e.g., an "isolated DNA" or an "isolated RNA") means a nucleic acid or nucleotide sequence separated or substantially free from at least some of the other components of the naturally occurring organism or virus, for example, the cell or viral structural components or other polypeptides or nucleic acids commonly found associated with the nucleic acid or nucleotide sequence.

[0041] Likewise, an "isolated" polypeptide means a polypeptide that is separated or substantially free from at least some of the other components of the naturally occurring organism or virus, for example, the cell or viral structural components or other polypeptides or nucleic acids commonly found associated with the polypeptide.

[0042] By the term "treat," "treating," or "treatment of" (or grammatically equivalent terms) it is meant that the severity of the subject's condition is reduced or at least partially improved or ameliorated and/or that some alleviation, mitigation or decrease in at least one clinical symptom is achieved and/or there is a delay in the progression of the condition and/or prevention or delay of the onset of a disease or disorder. The term "treat," "treats," "treating," or "treatment of" and the like also include prophylactic treatment of the subject (e.g., to prevent the onset of infection or cancer or a disorder). As used herein, the term "prevent," "prevents," or "prevention" (and grammatical equivalents thereof) are not meant to imply complete abolition of disease and encompasses any type of prophylactic treatment that reduces the incidence of the condition, delays the onset and/or progression of the condition, and/or reduces the symptoms associated with the condition. Thus, unless the context indicates otherwise, the term "treat," "treating," or "treatment of" (or grammatically equivalent terms) refer to both prophylactic and therapeutic regimens.

[0043] An "effective" or "therapeutically effective" amount as used herein is an amount that is sufficient to provide some improvement or benefit to the subject. Alternatively stated, an "effective" or "therapeutically effective" amount is an amount that will provide some alleviation, mitigation, or decrease in at least one clinical symptom in the subject. Those skilled in the art will appreciate that the therapeutic effects need not be complete or curative, as long as some benefit is provided to the subject.

[0044] A "heterologous nucleotide sequence" or "heterologous nucleic acid" is a sequence that is not naturally occurring in the virus. Generally, the heterologous nucleic acid or nucleotide sequence comprises an open reading frame that encodes a polypeptide and/or a nontranslated RNA.

[0045] A "therapeutic polypeptide" can be a polypeptide that can alleviate or reduce symptoms that result from an absence or defect in a protein in a cell or subject. In addition, a "therapeutic polypeptide" can be a polypeptide that otherwise confers a benefit to a subject, e.g., anti-cancer effects or improvement in transplant survivability.

[0046] As used herein, the term "vector," "virus vector," "delivery vector" (and similar terms) generally refers to a virus particle that functions as a nucleic acid delivery vehicle, and which comprises the viral nucleic acid (i.e., the vector genome) packaged within the virion. Virus vectors according to the present invention comprise a chimeric AAV capsid according to the invention and can package an AAV or rAAV genome or any other nucleic acid including viral nucleic acids. Alternatively, in some contexts, the term "vector," "virus vector," "delivery vector" (and similar terms) may be used to refer to the vector genome (e.g., vDNA) in the absence of the virion and/or to a viral capsid that acts as a transporter to deliver molecules tethered to the capsid or packaged within the capsid.

[0047] A "recombinant AAV vector genome" or "rAAV genome" is an AAV genome (i.e., vDNA) that comprises at least one inverted terminal repeat (e.g., one, two or three inverted terminal repeats) and one or more heterologous nucleotide sequences. rAAV vectors generally retain the 145 base terminal repeat(s) (TR(s)) in *cis* to generate virus; however, modified AAV TRs and non-AAV TRs including partially or completely synthetic sequences can also serve this purpose. All other viral sequences are dispensable and may be supplied in *trans* (Muzyczka, (1992) *Curr. Topics Microbiol. Immunol.* 158:97). The rAAV vector optionally comprises two TRs (e.g., AAV TRs), which generally will be at the 5' and 3' ends of the heterologous nucleotide sequence(s), but need not be contiguous thereto. The TRs can be the same or different from each other. The vector genome can also contain a single ITR at its 3' or 5' end.

[0048] The term "terminal repeat" or "TR" includes any viral terminal repeat or synthetic sequence that forms a hairpin structure and functions as an inverted terminal repeat (i.e., mediates the desired functions such as replication, virus packaging, integration and/or provirus rescue, and the like). The TR can be an AAV TR or a non-AAV TR. For example, a non-AAV TR sequence such as those of other parvoviruses (e.g., canine parvovirus (CPV), mouse parvovirus (MVM), human parvovirus B-19) or the SV40 hairpin that serves as the origin of SV40 replication can be used as a TR, which can further be modified by truncation, substitution, deletion, insertion and/or addition. Further, the TR can be partially or completely synthetic, such as the "double-D sequence" as described in United States Patent No. 5,478,745 to Samulski et al.

[0049] An "AAV terminal repeat" or "AAV TR" may be from any AAV, including but not limited to serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 or any other AAV now known or later discovered (see, e.g., **Table 1**). An AAV terminal repeat need not have the native terminal repeat sequence (e.g., a native AAV TR sequence may be altered by insertion, deletion, truncation and/or missense mutations), as long as the terminal repeat mediates the desired functions, e.g., replication, virus packaging, integration, and/or provirus rescue, and the like.

[0050] The terms "rAAV particle" and "rAAV virion" are used interchangeably here. A "rAAV particle" or "rAAV virion" comprises a rAAV vector genome packaged within an AAV capsid.

[0051] The AAV capsid structure is described in more detail in BERNARD N. FIELDS et al., *VIROLOGY*, volume 2, chapters 69 & 70 (4th ed., Lippincott-Raven Publishers).

[0052] By "substantially retain" a property, it is meant that at least about 75%, 85%, 90%, 95%, 97%, 98%, 99% or 100% of the property (e.g., activity or other measurable characteristic) is retained.

II. Chimeric AAV Capsids Targeted to Oligodendrocytes.

[0053] The inventors have identified chimeric AAV capsid structures capable of preferentially transducing oligodendrocytes over neurons and other cells of the CNS. Thus, one aspect of the invention relates to a nucleic acid encoding an AAV capsid, the nucleic acid comprising, consisting essentially of, or consisting of an AAV capsid coding sequence that is at least 90% identical to: (a) the nucleotide sequence of SEQ ID NO: 1; or (b) a nucleotide sequence encoding SEQ ID NO:2; and viruses comprising the chimeric AAV capsids. In some embodiments, the AAV capsid coding sequence is at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the nucleotide sequence of (a) or (b). In another embodiment, the AAV capsid coding sequence comprises, consist essentially of, or consist of the nucleotide sequence of (a) or (b).

AAV Capsid Nucleotide Sequence of BNP61 (SEQ ID NO: 1)

```

atggctgccg atggttatct tccagattgg ctcgaggaca ctctctctga 50
aggaataaga cagtgggtgga agctcaaacc tggcccacca ccaccaaagc 100
ccgcagagcg gcataaggac gacagcaggg gtcttgtgct tcctgggtac 150
aagtacctcg gacccttcaa cggactcgac aaggagagagc cggccaacga 200
ggcagacgcc gcggccctcg agcacgacaa agcctacgac cggcagctcg 250
acagcggaga caaccgtac ctcaagtaca accacgccga cgcggagttt 300
caggagcgcc ttaaagaaga tacgtctttt gggggcaacc tcgggcgagc 350
agtcttccag gccaaaaaga ggcttcttga acctcttggt ctggttgagg 400
aagcggctaa gacggctcct ggaaagaaga ggcctgtaga gcagtctcct 450
caggaaccgg actcctcctc gggcatcggc aagacaggcc agcagcccgc 500
taaaaagaga ctcaatttcg gtcagactgg cgacacagag tcagtcccag 550
accctcaacc aatcggagaa cctcccgcag cccctcagg tgtgggatct 600

```

EP 3 738 974 A1

	cttacaatgg	cttcaggtgg	tggcgcacca	gtggcagaca	ataacgaagg	650
	tgccgatgga	gtgggtagtt	cctcgggaaa	ttggcattgc	gattcccaat	700
	ggctggggga	cagagtcac	accaccagca	cccgaacctg	ggccctgccc	750
5	acctacaaca	atcacctcta	caagcaaata	tccaacggga	catcgggagg	800
	agccaccaac	gacaacacct	acttcggcta	cagcaccccc	tgggggtatt	850
	ttgactttta	cagattccac	tgccactttt	caccacgtga	ctggcagcga	900
	ctcatcaaca	acaactgggg	attccggccc	aagagactca	gcttcaagct	950
	cttcaacatc	caggtcaagg	aggtcacgca	gaatgaaggc	accaagacca	1000
10	tcgccaataa	ccttaccagc	acggtccagg	tcttcacgga	ctcggagtac	1050
	cagctgccgt	acgttctcgg	ctctgcccac	cagggctgcc	tgcctccgtt	1100
	cccggcggac	gtgttcatga	ttccccagta	cggctaccta	acactcaaca	1150
	acggtagtca	ggccgtggga	cgctcctcct	tctactgcct	ggaatacttt	1200
	ccttcgcaga	tgctgagaac	cggcaacaac	ttccagttta	cttacacctt	1250
15	cgaggacgtg	cctttccaca	gcagctacgc	ccacagccag	agcttggacc	1300
	ggctgatgaa	tcctctgatt	gaccagtacc	tgtactactt	gtctcggact	1350
	caaacaacag	gaggcacggc	aaatacgcag	actctgggct	tcagccaagg	1400
	tgggcctaata	acaatggcca	atcaggcaaa	gaactggctg	ccaggaccct	1450
20	gttaccgcca	acaacgcgtc	tcaacgacaa	ccgggcaaaa	caacaatagc	1500
	aactttgcct	ggactgctgg	gaccaaatac	catctgaatg	gaagaaattc	1550
	attggctaata	cctggcatcg	ctatggcaac	acacaaagac	gacaaggagc	1600
	gtttttttcc	cagtaacggg	atcctgattt	ttggcaaaca	aaatgctgcc	1650
	agagacaatg	cggattacag	cgatgtcatg	ctcaccagcg	aggaagaaat	1700
25	caaaaccact	aaccctgtgg	ctacagagga	atacggtatc	gtggcagata	1750
	acttgacgca	gcaaaacacg	gctcctcaaa	ttggaactgt	caacagccag	1800
	ggggccttac	ccggtatggt	ttggcagaac	cgggacgtgt	acctgcaggg	1850
	tcccatctgg	gccaagattc	ctcacacgga	cggcaacttc	caccgctctc	1900
	cgctgatggg	cggctttggc	ctgaaacatc	ctccgcctca	gatcctgatc	1950
30	aagaacacgc	ctgtacctgc	ggatcctccg	accaccttca	accagtcaaa	2000
	gctgaactct	ttcatcacgc	aatacagcac	cggacaggtc	agcgtggaaa	2050
	ttgaatggga	gctgcagaag	gaaaacagca	agcgtggaa	ccccgagatc	2100
	cagtacacct	ccaactacta	caaatctaca	agtgtggact	ttgctgttaa	2150
35	tacagaaggc	gtgtactctg	aacccccacc	cattggcacc	cgttacctca	2200
	cccgctcccct	gtaa				

AAV Capsid Amino Acid Sequence of BNP61 (SEQ ID NO:2)

40	MAADGYLPDW	LEDTLSEGIR	QWWKLKPGPP	PPKPAERHKD	DSRGLVLPGY	50
	KYLGPFNGLD	KGEPVNEADA	AALHDKAYD	RQLDSGDNPY	LKYNHADAEF	100
	QERLKEDTSF	GGNLGRAVFQ	AKKRLLEPLG	LVEEAAKTAP	GKKRPVEQSP	150
	QEPDSSSGIG	KTGQQPAKKR	LNFGQTGDTE	SVPDPQPIGE	PPAAPSGVGS	200
45	LTMASGGGAP	VADNNEGADG	VGSSSGNWHC	DSQWLGDRVI	TTSTRTWALP	250
	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYFDENRFH	CHFSPRDWQR	300
	LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TVQVFTDSEY	350
	QLPYVLGSAH	QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	400
	PSQMLRTGNN	FQFTYTFEDV	PFHSSYAHSQ	SLDRLMNPLI	DQYLYYLSRT	450
50	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	PGPCYRQQRV	STTTGQNNNS	500
	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DKERFFPSNG	ILIFGKQNAA	550
	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
	GALPGMVWQN	RDVYLQGPIW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	650
55	KNTPVPADPP	TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	700
	QYTSNYYKST	SVDFAVNTEG	VYSEPHPIGT	RYLTRPL		

[0054] In some embodiments, the nucleic acid encoding an AAV capsid comprises, consists essentially of, or consists

EP 3 738 974 A1

of an AAV capsid coding sequence that is at least 90% identical to a nucleotide sequence encoding SEQ ID NOS:3 or 4; and viruses comprising the chimeric AAV capsids. In some embodiments, the AAV capsid coding sequence is at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the nucleotide sequence encoding SEQ ID NOS:3 or 4. In another embodiment, the AAV capsid coding sequence comprises, consists essentially of, or consists of the nucleotide sequence encoding SEQ ID NOS:3 or 4.

AAV Capsid Amino Acid Sequence of BNP62 (SEQ ID NO:3)

```
10      MAADGYLPDW LEDNLSEGIR EWWDLKPGAP KPKANQQKQD DGRGLVLPGY 50
      KYLGPFNGLD KGEPVNAADA AALEHDKAYD QQLKAGDNPY LRYNHADAEF 100
      QERLQEDTSF GGNLGRAVFQ AKKRVLEPLG LVEEGAKTAP GKKRPVEQSP 150
15      QEPDSSSGIG KTGQQPAKKR LNFGQTDGTE SVPDPQPIGE PPAAPSGVGS 200
      LTMASGGGAP VADNNEGADG VGSSSGNWHC DSQWLGDRVI TTSTRTWALP 250
      TYNNHLYKQI SSASTGASND NHYFGYSTPW GYFDFNRFHC HFSPRDWQRL 300
20      INNNWGFPRK RLNFKLEFNIQ VKEVTDNNGV KTIANNLTST VQVFTDSDYQ 350
      LPYVLGSAHQ GCLPPFPADV FMIPQYGYLT LNNGSQAVGR SSFYCLEYFP 400
      SQMLRTGNNF QFTYTFEDVP FHSSYAHSQS LDRLMNPLID QYLYLSRTQ 450
      TTGGTANTQT LGFSQGGPNT MANQAKNWLP GPCYRQQRVS TTTGQNNNSN 500
25      FAWTAGTKYH LNGRNSLANP GIAMATHKDD KERFFPSNGI LIFGKQNAAR 550
      DNADYSDVML TSEEEIKTTN PVATEEYGIV ADNLQQQNTA PQIGTVNSQG 600
      ALPGMVWQNR DVYLQGPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK 650
30      NTPVPADPPT TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ 700
      YTSNYYKSTS VDFAVNTEGV YSEPHPIGTR YLTRPL
```

AAV Capsid Amino Acid Sequence of BNP63 (SEQ ID NO:4)

```
35      MAADGYLPDW LEDTLSEGIR QWWKLKPGPP PPKPAERHKD DSRGLVLPGY 50
      KYLGPFNGLD KGEPVNEADA AALEHDKAYD RQLDSGDNPY LKYNHADAEF 100
40      QERLQGDTSF GGNLGRAVFQ AKKRVLEPLG LVEEGAKTAP GKKRPVEQSP 150
      QEPDSSSGIG ETGQQPAKKR LNFGQTDGSE SVPDPQPLGE PPATPAAVGP 200
      TTMASGGGAP MADNNEGADG VGSSSGNWHC DSQWLGDRVI TTSTRTWALP 250
45      TYNNHLYKQI SSASTGASND NHYFGYSTPW GYFDFNRFHC HFSPRDWQRL 300
      INNNWGFPRK RLSFKLEFNIQ VKEVTDNNGV KTIANNLTST VQVFTDSEYQ 350
      LPYVLGSAHQ GCLPPFPADV FMIPQYGYLT LNNGSQAVGR SSFYCLEYFP 400
```

SQMLRTGNNF TFSYTFEDVP FHSSYAHSQS LDRLMNPLID QYLYYLSRTQ 450
 TTGGTANTQT LGFSQGGPNT MANQAKNWLP GPCYRQQRVS TTTGQNNNSN 500
 5 FAWTAGTKYH LNGRNSLANP GIAMATHKDD KERFFPSNGI LIFGKQNAAR 550
 DNADYSDVML TSEEEIKTTN PVATEEYGIV ADNLQQQNTA PQIGTVNSQG 600
 ALPGMVWQNR DVYLQGPiWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK 650
 10 NTPVPADPPT TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ 700
 YTSNYYKSTS VDFAVNTEGV YSEPHPIGTR YLTRPL

[0055] SEQ ID NOS:2-4 show examples of the VP1 capsid protein sequences of the invention. The designation of all amino acid positions in the description of the invention and the appended claims is with respect to VP1 numbering. Those skilled in the art will understand that the AAV capsid generally contains the smaller VP2 and VP3 capsid proteins as well. Due to the overlap of the coding sequences for the AAV capsid proteins, the nucleic acid coding sequences and amino acid sequences of the VP2 and VP3 capsid proteins will be apparent from the VP1 sequences shown in SEQ ID NOS: 1-4. In particular, VP2 starts at nucleotide 412 (acg) of SEQ ID NO: 1 and threonine 148 of SEQ ID NO:2. VP3 starts at nucleotide 607 (atg) of SEQ ID NO: 1 and methionine 203 of SEQ ID NO:2. In certain embodiments, isolated VP2 and VP3 capsid proteins comprising the sequence from SEQ ID NOS:2-4 and isolated nucleic acids encoding the VP2 or VP3 proteins, or both, are contemplated.

[0056] The invention also provides chimeric AAV capsid proteins and chimeric capsids, wherein the capsid protein comprises, consists essentially of, or consists of an amino acid sequence as shown in one of SEQ ID NOS:2-4, wherein 1, 2 or fewer, 3 or fewer, 4 or fewer, 5 or fewer, 6 or fewer, 7 or fewer, 8 or fewer, 9 or fewer, 10 or fewer, 12 or fewer, 15 or fewer, 20 or fewer, 25 or fewer, 30 or fewer, 40 or fewer, or 50 or fewer of the amino acids within the capsid protein coding sequence of one of SEQ ID NOS:2-4 is substituted by another amino acid (naturally occurring, modified and/or synthetic), optionally a conservative amino acid substitution, and/or are deleted and/or there are insertions (including N-terminal and C-terminal extensions) of 1, 2 or fewer, 3 or fewer, 4 or fewer, 5 or fewer, 6 or fewer, 7 or fewer, 8 or fewer, 9 or fewer, 10 or fewer, 12 or fewer, 15 or fewer, 20 or fewer, 25 or fewer, 30 or fewer, 40 or fewer, or 50 or fewer amino acids or any combination of substitutions, deletions and/or insertions, wherein the substitutions, deletions and/or insertions do not unduly impair the structure and/or function of a virion (e.g., an AAV virion) comprising the variant capsid protein or capsid. For example, in representative embodiments of the invention, an AAV virion comprising the chimeric capsid protein substantially retains at least one property of a chimeric virion comprising a chimeric capsid protein as shown in one of SEQ ID NOS:2-4. For example, the virion comprising the chimeric capsid protein can substantially retain the oligodendrocyte tropism profile of a virion comprising the chimeric AAV capsid protein as shown in one of SEQ ID NOS:2-4. Methods of evaluating biological properties such as virus transduction are well-known in the art (see, e.g., the Examples).

[0057] Conservative amino acid substitutions are known in the art. In particular embodiments, a conservative amino acid substitution includes substitutions within one or more of the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and/or phenylalanine, tyrosine.

[0058] It will be apparent to those skilled in the art that the amino acid sequences of the chimeric AAV capsid protein of SEQ ID NOS:2-4 can further be modified to incorporate other modifications as known in the art to impart desired properties. As nonlimiting possibilities, the capsid protein can be modified to incorporate targeting sequences (e.g., RGD) or sequences that facilitate purification and/or detection. For example, the capsid protein can be fused to all or a portion of glutathione-S-transferase, maltose-binding protein, a heparin/heparan sulfate binding domain, poly-His, a ligand, and/or a reporter protein (e.g., Green Fluorescent Protein, β -glucuronidase, β -galactosidase, luciferase, etc.), an immunoglobulin Fc fragment, a single-chain antibody, hemagglutinin, c-myc, FLAG epitope, and the like to form a fusion protein. Methods of inserting targeting peptides into the AAV capsid are known in the art (see, e.g., international patent publication WO 00/28004; Nicklin et al., (2001) Mol. Ther. 474-181; White et al., (2004) Circulation 109:513-319; Muller et al., (2003) Nature Biotech. 21:1040-1046.

[0059] The viruses of the invention can further comprise a duplexed viral genome as described in international patent publication WO 01/92551 and U.S. Patent No. 7,465,583.

[0060] The invention also provides AAV capsids comprising the chimeric AAV capsid proteins of the invention and virus particles (i.e., virions) comprising the same, wherein the virus particle packages (i.e., encapsidates) a vector genome, optionally an AAV vector genome. In particular embodiments, the invention provides an AAV particle comprising an AAV capsid comprising an AAV capsid protein of the invention, wherein the AAV capsid packages an AAV vector genome. The invention also provides an AAV particle comprising an AAV capsid or AAV capsid protein encoded by the

chimeric nucleic acid capsid coding sequences of the invention.

[0061] In particular embodiments, the virion is a recombinant vector comprising a heterologous nucleic acid of interest, e.g., for delivery to a cell. Thus, the present invention is useful for the delivery of nucleic acids to cells *in vitro*, *ex vivo*, and *in vivo*. In representative embodiments, the recombinant vector of the invention can be advantageously employed

to deliver or transfer nucleic acids to animal (e.g., mammalian) cells.

[0062] Any heterologous nucleotide sequence(s) may be delivered by a virus vector of the present invention. Nucleic acids of interest include nucleic acids encoding polypeptides, optionally therapeutic (e.g., for medical or veterinary uses) and/or immunogenic (e.g., for vaccines) polypeptides.

[0063] In some embodiments, the polypeptide is one that stimulates growth and/or differentiation of oligodendrocytes. Examples include, without limitation, insulin-like growth factor-1, glial-derived neurotrophic factor, neurotrophin-3, artemin, transforming growth factor alpha, platelet-derived growth factor, leukemia inhibitory factor, prolactin, monocarboxylate transporter 1, or nuclear factor 1A.

[0064] Therapeutic polypeptides include, but are not limited to, cystic fibrosis transmembrane regulator protein (CFTR), dystrophin (including the protein product of dystrophin mini-genes or micro-genes, see, e.g., Vincent et al., (1993) Nature Genetics 5:130; U.S. Patent Publication No. 2003017131; Wang et al., (2000) Proc. Natl. Acad. Sci. USA 97:13714-9 [mini-dystrophin]; Harper et al., (2002) Nature Med. 8:253-61 [micro-dystrophin]); mini-agrin, a laminin- α 2, a sarcoglycan (α , β , γ or δ), Fukutin-related protein, myostatin pro-peptide, follistatin, dominant negative myostatin, an angiogenic factor (e.g., VEGF, angiopoietin-1 or 2), an anti-apoptotic factor (e.g., heme-oxygenase-1, TGF- β , inhibitors of pro-apoptotic signals such as caspases, proteases, kinases, death receptors [e.g., CD-095], modulators of cytochrome C release, inhibitors of mitochondrial pore opening and swelling); activin type II soluble receptor, anti-inflammatory polypeptides such as the Ikappa B dominant mutant, sarcospan, utrophin, mini-utrophin, antibodies or antibody fragments against myostatin or myostatin propeptide, cell cycle modulators, Rho kinase modulators such as Cethrin, which is a modified bacterial C3 exoenzyme [available from BioAxone Therapeutics, Inc., Saint-Lauren, Quebec, Canada], BCL-xL, BCL2, XIAP, FLICEc-s, dominant-negative caspase-8, dominant negative caspase-9, SPI-6 (see, e.g., U.S. Patent Application No. 20070026076), transcriptional factor PGC- α 1, Pinch gene, ILK gene and thymosin β 4 gene), clotting factors (e.g., Factor VIII, Factor IX, Factor X, etc.), erythropoietin, angiostatin, endostatin, catalase, tyrosine hydroxylase, an intracellular and/or extracellular superoxide dismutase, leptin, the LDL receptor, neprilysin, lipoprotein lipase, ornithine transcarbamylase, β -globin, α -globin, spectrin, α_1 -antitrypsin, adenosine deaminase, hypoxanthine guanine phosphoribosyl transferase, β -glucocerebrosidase, sphingomyelinase, lysosomal hexosaminidase A, branched-chain keto acid dehydrogenase, RP65 protein, a cytokine (e.g., α -interferon, β -interferon, interferon- γ , interleukins-1 through -14, granulocyte-macrophage colony stimulating factor, lymphotoxin, and the like), peptide growth factors, neurotrophic factors and hormones (e.g., somatotropin, insulin, insulin-like growth factors including IGF-1 and IGF-2, GLP-1, platelet derived growth factor, epidermal growth factor, fibroblast growth factor, nerve growth factor, neurotrophic factor -3 and -4, brain-derived neurotrophic factor, glial derived growth factor, transforming growth factor - α and - β , and the like), bone morphogenic proteins (including RANKL and VEGF), a lysosomal protein, a glutamate receptor, a lymphokine, soluble CD4, an Fc receptor, a T cell receptor, ApoE, ApoC, inhibitor 1 of protein phosphatase inhibitor 1 (I-1), phospholamban, serca2a, lysosomal acid α -glucosidase, α -galactosidase A, Barkct, β 2-adrenergic receptor, β 2-adrenergic receptor kinase (BARK), phosphoinositide-3 kinase (PI3 kinase), calsarcin, a receptor (e.g., the tumor necrosis growth factor- α soluble receptor), an anti-inflammatory factor such as IRAP, Pim-1, PGC-1a, SOD-1, SOD-2, ECF-SOD, kallikrein, thymosin- β 4, hypoxia-inducible transcription factor [HIF], an angiogenic factor, S100A1, parvalbumin, adenylyl cyclase type 6, a molecule that effects G-protein coupled receptor kinase type 2 knockdown such as a truncated constitutively active bARKct; phospholamban inhibitory or dominant-negative molecules such as phospholamban S16E, a monoclonal antibody (including single chain monoclonal antibodies) or a suicide gene product (e.g., thymidine kinase, cytosine deaminase, diphtheria toxin, and tumor necrosis factors such as TNF- α), and any other polypeptide that has a therapeutic effect in a subject in need thereof.

[0065] Heterologous nucleotide sequences encoding polypeptides include those encoding reporter polypeptides (e.g., an enzyme). Reporter polypeptides are known in the art and include, but are not limited to, Green Fluorescent Protein, β -galactosidase, alkaline phosphatase, luciferase, and chloramphenicol acetyltransferase.

[0066] Alternatively, the heterologous nucleic acid may encode an antisense oligonucleotide, a ribozyme (e.g., as described in U.S. Patent No. 5,877,022), RNAs that effect spliceosome-mediated *trans*-splicing (see, Puttaraju et al., (1999) Nature Biotech. 17:246; U. S. Patent No. 6,013,487; U. S. Patent No. 6,083,702), interfering RNAs (RNAi) including small interfering RNAs (siRNA) that mediate gene silencing (see, Sharp et al., (2000) Science 287:2431), microRNA, or other non-translated "functional" RNAs, such as "guide" RNAs (Gorman et al., (1998) Proc. Nat. Acad. Sci. USA 95:4929; U.S. Patent No. 5,869,248 to Yuan et al.), and the like. Exemplary untranslated RNAs include RNAi or antisense RNA against the multiple drug resistance (MDR) gene product (e.g., to treat tumors and/or for administration to the heart to prevent damage by chemotherapy), RNAi or antisense RNA against myostatin (Duchenne or Becker muscular dystrophy), RNAi or antisense RNA against VEGF or a tumor immunogen including but not limited to those tumor immunogens specifically described herein (to treat tumors), RNAi or antisense oligonucleotides targeting mutated dystrophins (Duch-

enne or Becker muscular dystrophy), RNAi or antisense RNA against the hepatitis B surface antigen gene (to prevent and/or treat hepatitis B infection), RNAi or antisense RNA against the HIV tat and/or rev genes (to prevent and/or treat HIV) and/or RNAi or antisense RNA against any other immunogen from a pathogen (to protect a subject from the pathogen) or a defective gene product (to prevent or treat disease). RNAi or antisense RNA against the targets described

above or any other target can also be employed as a research reagent.

[0067] As is known in the art, anti-sense nucleic acids (e.g., DNA or RNA) and inhibitory RNA (e.g., microRNA and RNAi such as siRNA or shRNA) sequences can be used to induce "exon skipping" in patients with muscular dystrophy arising from defects in the dystrophin gene. Thus, the heterologous nucleic acid can encode an antisense nucleic acid or inhibitory RNA that induces appropriate exon skipping. Those skilled in the art will appreciate that the particular approach to exon skipping depends upon the nature of the underlying defect in the dystrophin gene, and numerous such strategies are known in the art. Exemplary antisense nucleic acids and inhibitory RNA sequences target the upstream branch point and/or downstream donor splice site and/or internal splicing enhancer sequence of one or more of the dystrophin exons (e.g., exons 19 or 23). For example, in particular embodiments, the heterologous nucleic acid encodes an antisense nucleic acid or inhibitory RNA directed against the upstream branch point and downstream splice donor site of exon 19 or 23 of the dystrophin gene. Such sequences can be incorporated into an AAV vector delivering a modified U7 snRNA and the antisense nucleic acid or inhibitory RNA (see, e.g., Goyenvallé et al., (2004) Science 306:1796-1799). As another strategy, a modified U1 snRNA can be incorporated into an AAV vector along with siRNA, microRNA or antisense RNA complementary to the upstream and downstream splice sites of a dystrophin exon (e.g., exon 19 or 23) (see, e.g., Denti et al., (2006) Proc. Natl. Acad. Sci. USA 103:3758-3763). Further, antisense nucleic acids and inhibitory RNA can target the splicing enhancer sequences within exons 19, 43, 45 or 53 (see, e.g., U.S. Patent No. 6,653,467; U.S. Patent No. 6,727,355; and U.S. Patent No. 6,653,466).

[0068] Ribozymes are RNA-protein complexes that cleave nucleic acids in a site-specific fashion. Ribozymes have specific catalytic domains that possess endonuclease activity (Kim et al., (1987) Proc. Natl. Acad. Sci. USA 84:8788; Gerlach et al., (1987) Nature 328:802; Forster and Symons, (1987) Cell 49:211). For example, a large number of ribozymes accelerate phosphoester transfer reactions with a high degree of specificity, often cleaving only one of several phosphoesters in an oligonucleotide substrate (Michel and Westhof, (1990) J. Mol. Biol. 216:585; Reinhold-Hurek and Shub, (1992) Nature 357:173). This specificity has been attributed to the requirement that the substrate bind via specific base-pairing interactions to the internal guide sequence ("IGS") of the ribozyme prior to chemical reaction.

[0069] Ribozyme catalysis has primarily been observed as part of sequence-specific cleavage/ligation reactions involving nucleic acids (Joyce, (1989) Nature 338:217). For example, U.S. Pat. No. 5,354,855 reports that certain ribozymes can act as endonucleases with a sequence specificity greater than that of known ribonucleases and approaching that of the DNA restriction enzymes. Thus, sequence-specific ribozyme-mediated inhibition of nucleic acid expression may be particularly suited to therapeutic applications (Scanlon et al., (1991) Proc. Natl. Acad. Sci. USA 88:10591; Sarver et al., (1990) Science 247:1222; Sioud et al., (1992) J. Mol. Biol. 223:831).

[0070] MicroRNAs (mir) are natural cellular RNA molecules that can regulate the expression of multiple genes by controlling the stability of the mRNA. Over-expression or diminution of a particular microRNA can be used to treat a dysfunction and has been shown to be effective in a number of disease states and animal models of disease (see, e.g., Couzin, (2008) Science 319:1782-4). The chimeric AAV can be used to deliver microRNA into cells, tissues and subjects for the treatment of genetic and acquired diseases, or to enhance functionality and promote growth of certain tissues. For example, mir-1, mir-133, mir-206 and/or mir-208 can be used to treat cardiac and skeletal muscle disease (see, e.g., Chen et al., (2006) Genet. 38:228-33; van Rooij et al., (2008) Trends Genet. 24:159-66). MicroRNA can also be used to modulate the immune system after gene delivery (Brown et al., (2007) Blood 110:4144-52).

[0071] The term "antisense oligonucleotide" (including "antisense RNA") as used herein, refers to a nucleic acid that is complementary to and specifically hybridizes to a specified DNA or RNA sequence. Antisense oligonucleotides and nucleic acids that encode the same can be made in accordance with conventional techniques. See, e.g., U.S. Patent No. 5,023,243 to Tullis; U.S. Patent No. 5,149,797 to Pederson et al.

[0072] Those skilled in the art will appreciate that it is not necessary that the antisense oligonucleotide be fully complementary to the target sequence as long as the degree of sequence similarity is sufficient for the antisense nucleotide sequence to specifically hybridize to its target (as defined above) and reduce production of the protein product (e.g., by at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more).

[0073] To determine the specificity of hybridization, hybridization of such oligonucleotides to target sequences can be carried out under conditions of reduced stringency, medium stringency or even stringent conditions. Suitable conditions for achieving reduced, medium and stringent hybridization conditions are as described herein.

[0074] Alternatively stated, in particular embodiments, antisense oligonucleotides of the invention have at least about 60%, 70%, 80%, 90%, 95%, 97%, 98% or higher sequence identity with the complement of the target sequence and reduce production of the protein product (as defined above). In some embodiments, the antisense sequence contains 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mismatches as compared with the target sequence.

[0075] Methods of determining percent identity of nucleic acid sequences are described in more detail elsewhere herein.

[0076] The length of the antisense oligonucleotide is not critical as long as it specifically hybridizes to the intended target and reduces production of the protein product (as defined above) and can be determined in accordance with routine procedures. In general, the antisense oligonucleotide is at least about eight, ten or twelve or fifteen nucleotides in length and/or less than about 20, 30, 40, 50, 60, 70, 80, 100 or 150 nucleotides in length.

[0077] RNA interference (RNAi) is another useful approach for reducing production of a protein product (e.g., shRNA or siRNA). RNAi is a mechanism of post-transcriptional gene silencing in which double-stranded RNA (dsRNA) corresponding to a target sequence of interest is introduced into a cell or an organism, resulting in degradation of the corresponding mRNA. The mechanism by which RNAi achieves gene silencing has been reviewed in Sharp et al., (2001) *Genes Dev* 15: 485-490; and Hammond et al., (2001) *Nature Rev. Gen.* 2:110-119). The RNAi effect persists for multiple cell divisions before gene expression is regained. RNAi is therefore a powerful method for making targeted knockouts or "knockdowns" at the RNA level. RNAi has proven successful in human cells, including human embryonic kidney and HeLa cells (see, e.g., Elbashir et al., *Nature* (2001) 411:494-8).

[0078] Initial attempts to use RNAi in mammalian cells resulted in antiviral defense mechanisms involving PKR in response to the dsRNA molecules (see, e.g., Gil et al., (2000) *Apoptosis* 5:107). It has since been demonstrated that short synthetic dsRNA of about 21 nucleotides, known as "short interfering RNAs" (siRNA) can mediate silencing in mammalian cells without triggering the antiviral response (see, e.g., Elbashir et al., *Nature* (2001) 411:494-8; Caplen et al., (2001) *Proc. Nat. Acad. Sci. USA* 98:9742).

[0079] The RNAi molecule (including an siRNA molecule) can be a short hairpin RNA (shRNA; see Paddison et al., (2002), *Proc. Nat. Acad. Sci. USA* 99:1443-1448), which is believed to be processed in the cell by the action of the RNase III like enzyme Dicer into 20-25mer siRNA molecules. The shRNAs generally have a stem-loop structure in which two inverted repeat sequences are separated by a short spacer sequence that loops out. There have been reports of shRNAs with loops ranging from 3 to 23 nucleotides in length. The loop sequence is generally not critical. Exemplary loop sequences include the following motifs: AUG, CCC, UUCG, CCACC, CTCGAG, AAGCUU, CCACACC and UUCAAGAGA.

[0080] The RNAi can further comprise a circular molecule comprising sense and antisense regions with two loop regions on either side to form a "dumbbell" shaped structure upon dsRNA formation between the sense and antisense regions. This molecule can be processed *in vitro* or *in vivo* to release the dsRNA portion, e.g., a siRNA.

[0081] International patent publication WO 01/77350 describes a vector for bidirectional transcription to generate both sense and antisense transcripts of a heterologous sequence in a eukaryotic cell. This technique can be employed to produce RNAi for use according to the invention.

[0082] Shinagawa et al., (2003) *Genes Dev.* 17:1340 reported a method of expressing long dsRNAs from a CMV promoter (a pol II promoter), which method is also applicable to tissue specific pol II promoters. Likewise, the approach of Xia et al., (2002) *Nature Biotech.* 20:1006, avoids poly(A) tailing and can be used in connection with tissue-specific promoters.

[0083] Methods of generating RNAi include chemical synthesis, *in vitro* transcription, digestion of long dsRNA by Dicer (*in vitro* or *in vivo*), expression *in vivo* from a delivery vector, and expression *in vivo* from a PCR-derived RNAi expression cassette (see, e.g., TechNotes 10(3) "Five Ways to Produce siRNAs," from Ambion, Inc., Austin TX; available at www.ambion.com).

[0084] Guidelines for designing siRNA molecules are available (see e.g., literature from Ambion, Inc., Austin TX; available at www.ambion.com). In particular embodiments, the siRNA sequence has about 30-50% G/C content. Further, long stretches of greater than four T or A residues are generally avoided if RNA polymerase III is used to transcribe the RNA. Online siRNA target finders are available, e.g., from Ambion, Inc. (www.ambion.com), through the Whitehead Institute of Biomedical Research (www.jura.wi.mit.edu) or from Dharmacon Research, Inc. (www.dharmacon.com).

[0085] The antisense region of the RNAi molecule can be completely complementary to the target sequence, but need not be as long as it specifically hybridizes to the target sequence (as defined above) and reduces production of the protein product (e.g., by at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more). In some embodiments, hybridization of such oligonucleotides to target sequences can be carried out under conditions of reduced stringency, medium stringency or even stringent conditions, as defined above.

[0086] In other embodiments, the antisense region of the RNAi has at least about 60%, 70%, 80%, 90%, 95%, 97%, 98% or higher sequence identity with the complement of the target sequence and reduces production of the protein product (e.g., by at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more). In some embodiments, the antisense region contains 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mismatches as compared with the target sequence. Mismatches are generally tolerated better at the ends of the dsRNA than in the center portion.

[0087] In particular embodiments, the RNAi is formed by intermolecular complexing between two separate sense and antisense molecules. The RNAi comprises a double stranded region formed by the intermolecular basepairing between the two separate strands. In other embodiments, the RNAi comprises a ds region formed by intramolecular basepairing within a single nucleic acid molecule comprising both sense and antisense regions, typically as an inverted repeat (e.g., a shRNA or other stem loop structure, or a circular RNAi molecule). The RNAi can further comprise a spacer region

between the sense and antisense regions.

[0088] Generally, RNAi molecules are highly selective. If desired, those skilled in the art can readily eliminate candidate RNAi that are likely to interfere with expression of nucleic acids other than the target by searching relevant databases to identify RNAi sequences that do not have substantial sequence homology with other known sequences, for example, using BLAST (available at www.ncbi.nlm.nih.gov/BLAST).

[0089] Kits for the production of RNAi are commercially available, e.g., from New England Biolabs, Inc. and Ambion, Inc.

[0090] The recombinant virus vector may also comprise a heterologous nucleotide sequence that shares homology with and recombines with a locus on the host chromosome. This approach may be utilized to correct a genetic defect in the host cell.

[0091] The present invention also provides recombinant virus vectors that express an immunogenic polypeptide, e.g., for vaccination. The heterologous nucleic acid may encode any immunogen of interest known in the art including, but are not limited to, immunogens from human immunodeficiency virus, influenza virus, gag proteins, tumor antigens, cancer antigens, bacterial antigens, viral antigens, and the like. Alternatively, the immunogen can be presented in the virus capsid (e.g., incorporated therein) or tethered to the virus capsid (e.g., by covalent modification).

[0092] The use of parvoviruses as vaccines is known in the art (see, e.g., Miyamura et al., (1994) Proc. Nat. Acad. Sci. USA 91:8507; U. S. Patent No. 5,916,563 to Young et al., 5,905,040 to Mazzara et al., U.S. Patent No. 5,882,652, U.S. Patent No. 5,863,541 to Samulski et al.). The antigen may be presented in the virus capsid. Alternatively, the antigen may be expressed from a heterologous nucleic acid introduced into a recombinant vector genome.

[0093] An immunogenic polypeptide, or immunogen, may be any polypeptide suitable for protecting the subject against a disease, including but not limited to microbial, bacterial, protozoal, parasitic, fungal and viral diseases. For example, the immunogen may be an orthomyxovirus immunogen (e.g., an influenza virus immunogen, such as the influenza virus hemagglutinin (HA) surface protein or the influenza virus nucleoprotein gene, or an equine influenza virus immunogen), or a lentivirus immunogen (e.g., an equine infectious anemia virus immunogen, a Simian Immunodeficiency Virus (SIV) immunogen, or a Human Immunodeficiency Virus (HIV) immunogen, such as the HIV or SIV envelope GP160 protein, the HIV or SIV matrix/capsid proteins, and the HIV or SIV *gag*, *pol* and *env* genes products). The immunogen may also be an arenavirus immunogen (e.g., Lassa fever virus immunogen, such as the Lassa fever virus nucleocapsid protein gene and the Lassa fever envelope glycoprotein gene), a poxvirus immunogen (e.g., vaccinia, such as the vaccinia L1 or L8 genes), a flavivirus immunogen (e.g., a yellow fever virus immunogen or a Japanese encephalitis virus immunogen), a filovirus immunogen (e.g., an Ebola virus immunogen, or a Marburg virus immunogen, such as NP and GP genes), a bunyavirus immunogen (e.g., RVFV, CCHF, and SFS viruses), or a coronavirus immunogen (e.g., an infectious human coronavirus immunogen, such as the human coronavirus envelope glycoprotein gene, or a porcine transmissible gastroenteritis virus immunogen, or an avian infectious bronchitis virus immunogen, or a severe acute respiratory syndrome (SARS) immunogen such as a S [S1 or S2], M, E, or N protein or an immunogenic fragment thereof). The immunogen may further be a polio immunogen, herpes immunogen (e.g., CMV, EBV, HSV immunogens) mumps immunogen, measles immunogen, rubella immunogen, diphtheria toxin or other diphtheria immunogen, pertussis antigen, hepatitis (e.g., hepatitis A, hepatitis B or hepatitis C) immunogen, or any other vaccine immunogen known in the art.

[0094] Alternatively, the immunogen may be any tumor or cancer cell antigen. Optionally, the tumor or cancer antigen is expressed on the surface of the cancer cell. Exemplary cancer and tumor cell antigens are described in S.A. Rosenberg, (1999) Immunity 10:281. Illustrative cancer and tumor antigens include, but are not limited to: BRCA1 gene product, BRCA2 gene product, gp100, tyrosinase, GAGE-1/2, BAGE, RAGE, NY-ESO-1, CDK-4, β -catenin, MUM-1, Caspase-8, KIAA0205, HPVE, SART-1, PRAME, p15, melanoma tumor antigens (Kawakami et al., (1994) Proc. Natl. Acad. Sci. USA 91:3515; Kawakami et al., (1994) J. Exp. Med., 180:347; Kawakami et al., (1994) Cancer Res. 54:3124) including MART-1 (Coulie et al., (1991) J. Exp. Med. 180:35), gp100 (Wick et al., (1988) J. Cutan. Pathol. 4:201) and MAGE antigen (MAGE-1, MAGE-2 and MAGE-3) (Van der Bruggen et al., (1991) Science, 254:1643), CEA, TRP-1; TRP-2; P-15 and tyrosinase (Brichard et al., (1993) J. Exp. Med. 178:489); HER-2/neu gene product (U.S. Pat. No. 4,968,603); CA 125; HE4; LK26; FB5 (endosialin); TAG 72; AFP; CA19-9; NSE; DU-PAN-2; CA50; Span-1; CA72-4; HCG; STN (sialyl Tn antigen); c-erbB-2 proteins; PSA; L-CanAg; estrogen receptor; milk fat globulin; p53 tumor suppressor protein (Levine, (1993) Ann. Rev. Biochem. 62:623); mucin antigens (international patent publication WO 90/05142); telomerase; nuclear matrix proteins; prostatic acid phosphatase; papilloma virus antigens; and antigens associated with the following cancers: melanomas, adenocarcinoma, thymoma, sarcoma, lung cancer, liver cancer, colorectal cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukemias, uterine cancer, breast cancer, prostate cancer, ovarian cancer, cervical cancer, bladder cancer, kidney cancer, pancreatic cancer, brain cancer, kidney cancer, stomach cancer, esophageal cancer, head and neck cancer and others (see, e.g., Rosenberg, (1996) Annu. Rev. Med. 47:481-91).

[0095] Alternatively, the heterologous nucleotide sequence may encode any polypeptide that is desirably produced in a cell *in vitro*, *ex vivo*, or *in vivo*. For example, the virus vectors may be introduced into cultured cells and the expressed protein product isolated therefrom.

[0096] It will be understood by those skilled in the art that the heterologous nucleic acid(s) of interest may be operably associated with appropriate control sequences. For example, the heterologous nucleic acid may be operably associated

with expression control elements, such as transcription/translation control signals, origins of replication, polyadenylation signals, internal ribosome entry sites (IRES), promoters, enhancers, and the like.

[0097] Those skilled in the art will further appreciate that a variety of promoter/enhancer elements may be used depending on the level and tissue-specific expression desired. The promoter/enhancer may be constitutive or inducible, depending on the pattern of expression desired. The promoter/enhancer may be native or foreign and can be a natural or a synthetic sequence. By foreign, it is intended that the transcriptional initiation region is not found in the wild-type host into which the transcriptional initiation region is introduced.

[0098] Promoter/enhancer elements can be native to the target cell or subject to be treated and/or native to the heterologous nucleic acid sequence. The promoter/enhancer element is generally chosen so that it will function in the target cell(s) of interest. In representative embodiments, the promoter/enhancer element is a mammalian promoter/enhancer element. The promoter/enhancer element may be constitutive or inducible.

[0099] Inducible expression control elements are generally used in those applications in which it is desirable to provide regulation over expression of the heterologous nucleic acid sequence(s). Inducible promoters/enhancer elements for gene delivery can be tissue-specific or tissue-preferred promoter/enhancer elements, and include muscle specific or preferred (including cardiac, skeletal and/or smooth muscle), neural tissue specific or preferred (including brain-specific), eye (including retina-specific and cornea-specific), liver specific or preferred, bone marrow specific or preferred, pancreatic specific or preferred, spleen specific or preferred, and lung specific or preferred promoter/enhancer elements. In one embodiment, an oligodendrocyte-specified or oligodendrocyte-preferred promoter is used. Examples include, without limitation, myelin basic protein, cyclic nucleotide phosphodiesterase, proteolipid protein, Gtx, and Sox10. Use of an oligodendrocyte-specific or preferred promoter can increase the specificity achieved by the chimeric AAV vector by further limiting expression of the heterologous nucleic acid to oligodendrocytes. Other inducible promoter/enhancer elements include hormone-inducible and metal-inducible elements. Exemplary inducible promoters/enhancer elements include, but are not limited to, a Tet on/off element, a RU486-inducible promoter, an ecdysone-inducible promoter, a rapamycin-inducible promoter, and a metallothionein promoter.

[0100] In embodiments wherein the heterologous nucleic acid sequence(s) is transcribed and then translated in the target cells, specific initiation signals are generally employed for efficient translation of inserted protein coding sequences. These exogenous translational control sequences, which may include the ATG initiation codon and adjacent sequences, can be of a variety of origins, both natural and synthetic.

[0101] The invention also provides chimeric AAV particles comprising an AAV capsid and an AAV genome, wherein the AAV genome "corresponds to" (*i.e.*, encodes) the AAV capsid. Also provided are collections or libraries of such chimeric AAV particles, wherein the collection or library comprises 2 or more, 10 or more, 50 or more, 100 or more, 1000 or more, 10^4 or more, 10^5 or more, or 10^6 or more distinct sequences.

[0102] The present invention further encompasses "empty" capsid particles (*i.e.*, in the absence of a vector genome) comprising, consisting of, or consisting essentially of the chimeric AAV capsid proteins of the invention. The chimeric AAV capsids of the invention can be used as "capsid vehicles," as has been described in U.S. Patent No. 5,863,541. Molecules that can be covalently linked, bound to or packaged by the virus capsids and transferred into a cell include DNA, RNA, a lipid, a carbohydrate, a polypeptide, a small organic molecule, or combinations of the same. Further, molecules can be associated with (*e.g.*, "tethered to") the outside of the virus capsid for transfer of the molecules into host target cells. In one embodiment of the invention the molecule is covalently linked (*i.e.*, conjugated or chemically coupled) to the capsid proteins. Methods of covalently linking molecules are known by those skilled in the art.

[0103] The virus capsids of the invention also find use in raising antibodies against the novel capsid structures. As a further alternative, an exogenous amino acid sequence may be inserted into the virus capsid for antigen presentation to a cell, *e.g.*, for administration to a subject to produce an immune response to the exogenous amino acid sequence.

[0104] The invention also provides nucleic acids (*e.g.*, isolated nucleic acids) encoding the chimeric virus capsids and chimeric capsid proteins of the invention. Further provided are vectors comprising the nucleic acids, and cells (*in vivo* or in culture) comprising the nucleic acids and/or vectors of the invention. Such nucleic acids, vectors and cells can be used, for example, as reagents (*e.g.*, helper constructs or packaging cells) for the production of virus vectors as described herein.

[0105] In exemplary embodiments, the invention provides nucleic acid sequences encoding the AAV capsid of SEQ ID NOS:2-4 or at least 90% identical to the nucleotide sequence of SEQ ID NO: 1. The invention also provides nucleic acids encoding the AAV capsid variants, capsid protein variants and fusion proteins as described above. In particular embodiments, the nucleic acid hybridizes to the complement of the nucleic acid sequences specifically disclosed herein under standard conditions as known by those skilled in the art and encodes a variant capsid and/or capsid protein. Optionally, the variant capsid or capsid protein substantially retains at least one property of the capsid and/or capsid or capsid protein encoded by the nucleic acid sequence of SEQ ID NO: 1. For example, a virus particle comprising the variant capsid or variant capsid protein can substantially retain the oligodendrocyte tropism profile of a virus particle comprising a capsid or capsid protein encoded by a nucleic acid coding sequence of SEQ ID NO: 1.

[0106] For example, hybridization of such sequences may be carried out under conditions of reduced stringency,

medium stringency or even stringent conditions. Exemplary conditions for reduced, medium and stringent hybridization are as follows: (e.g., conditions represented by a wash stringency of 35-40% Formamide with 5x Denhardt's solution, 0.5% SDS and 1x SSPE at 37°C; conditions represented by a wash stringency of 40-45% Formamide with 5x Denhardt's solution, 0.5% SDS, and 1x SSPE at 42°C; and conditions represented by a wash stringency of 50% Formamide with 5x Denhardt's solution, 0.5% SDS and 1x SSPE at 42°C, respectively). See, e.g., Sambrook et al., *Molecular Cloning, A Laboratory Manual* (2d Ed. 1989) (Cold Spring Harbor Laboratory).

[0107] In other embodiments, nucleic acid sequences encoding a variant capsid or capsid protein of the invention have at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher sequence identity with the nucleic acid sequence of SEQ ID NO: 1 and optionally encode a variant capsid or capsid protein that substantially retains at least one property of the capsid or capsid protein encoded by a nucleic acid of SEQ ID NO: 1.

[0108] As is known in the art, a number of different programs can be used to identify whether a nucleic acid or polypeptide has sequence identity to a known sequence. Percent identity as used herein means that a nucleic acid or fragment thereof shares a specified percent identity to another nucleic acid, when optimally aligned (with appropriate nucleotide insertions or deletions) with the other nucleic acid (or its complementary strand), using BLASTN. To determine percent identity between two different nucleic acids, the percent identity is to be determined using the BLASTN program "BLAST 2 sequences". This program is available for public use from the National Center for Biotechnology Information (NCBI) over the Internet (Altschul et al., (1997) *Nucleic Acids Res.* 25(17):3389-3402). The parameters to be used are whatever combination of the following yields the highest calculated percent identity (as calculated below) with the default parameters shown in parentheses: Program--blastn Matrix--O BLOSUM62 Reward for a match--0 or 1 (1) Penalty for a mismatch--0, -1, -2 or -3 (-2) Open gap penalty--0, 1, 2, 3, 4 or 5 (5) Extension gap penalty--0 or 1 (1) Gap x_dropoff--0 or 50 (50) Expect--10.

[0109] Percent identity or similarity when referring to polypeptides, indicates that the polypeptide in question exhibits a specified percent identity or similarity when compared with another protein or a portion thereof over the common lengths as determined using BLASTP. This program is also available for public use from the National Center for Biotechnology Information (NCBI) over the Internet (Altschul et al., (1997) *Nucleic Acids Res.* 25(17):3389-3402). Percent identity or similarity for polypeptides is typically measured using sequence analysis software. See, e.g., the Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 910 University Avenue, Madison, Wis. 53705. Protein analysis software matches similar sequences using measures of homology assigned to various substitutions, deletions and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

[0110] In particular embodiments, the nucleic acid can comprise, consist essentially of, or consist of a vector including but not limited to a plasmid, phage, viral vector (e.g., AAV vector, an adenovirus vector, a herpesvirus vector, or a baculovirus vector), bacterial artificial chromosome (BAC), or yeast artificial chromosome (YAC). For example, the nucleic acid can comprise, consist of, or consist essentially of an AAV vector comprising a 5' and/or 3' terminal repeat (e.g., 5' and/or 3' AAV terminal repeat).

[0111] In some embodiments, the nucleic acid encoding the chimeric AAV capsid protein further comprises an AAV rep coding sequence. For example, the nucleic acid can be a helper construct for producing viral stocks.

[0112] The invention also provides packaging cells stably comprising a nucleic acid of the invention. For example, the nucleic acid can be stably incorporated into the genome of the cell or can be stably maintained in an episomal form (e.g., an "EBV based nuclear episome").

[0113] The nucleic acid can be incorporated into a delivery vector, such as a viral delivery vector. To illustrate, the nucleic acid of the invention can be packaged in an AAV particle, an adenovirus particle, a herpesvirus particle, a baculovirus particle, or any other suitable virus particle.

[0114] Moreover, the nucleic acid can be operably associated with a promoter element. Promoter elements are described in more detail herein.

[0115] The present invention further provides methods of producing the virus vectors of the invention. In a representative embodiment, the present invention provides a method of producing a recombinant virus vector, the method comprising providing to a cell *in vitro*, (a) a template comprising (i) a heterologous nucleic acid, and (ii) packaging signal sequences sufficient for the encapsidation of the AAV template into virus particles (e.g., one or more (e.g., two) terminal repeats, such as AAV terminal repeats), and (b) AAV sequences sufficient for replication and encapsidation of the template into viral particles (e.g., the AAV *rep* and AAV *cap* sequences encoding an AAV capsid of the invention). The template and AAV replication and capsid sequences are provided under conditions such that recombinant virus particles comprising the template packaged within the capsid are produced in the cell. The method can further comprise the step of collecting the virus particles from the cell. Virus particles may be collected from the medium and/or by lysing the cells.

[0116] In one illustrative embodiment, the invention provides a method of producing a rAAV particle comprising an AAV capsid, the method comprising: providing a cell *in vitro* with a nucleic acid encoding a chimeric AAV capsid of the invention, an AAV rep coding sequence, an AAV vector genome comprising a heterologous nucleic acid, and helper

functions for generating a productive AAV infection; and allowing assembly of the AAV particles comprising the AAV capsid and encapsidating the AAV vector genome.

[0117] The cell is typically a cell that is permissive for AAV viral replication. Any suitable cell known in the art may be employed, such as mammalian cells. Also suitable are trans-complementing packaging cell lines that provide functions deleted from a replication-defective helper virus, e.g., 293 cells or other E1a trans-complementing cells.

[0118] The AAV replication and capsid sequences may be provided by any method known in the art. Current protocols typically express the AAV *rep/cap* genes on a single plasmid. The AAV replication and packaging sequences need not be provided together, although it may be convenient to do so. The AAV *rep* and/or *cap* sequences may be provided by any viral or non-viral vector. For example, the *rep/cap* sequences may be provided by a hybrid adenovirus or herpesvirus vector (e.g., inserted into the E1a or E3 regions of a deleted adenovirus vector). EBV vectors may also be employed to express the AAV *cap* and *rep* genes. One advantage of this method is that EBV vectors are episomal, yet will maintain a high copy number throughout successive cell divisions (i.e., are stably integrated into the cell as extrachromosomal elements, designated as an EBV based nuclear episome).

[0119] As a further alternative, the *rep/cap* sequences may be stably carried (episomal or integrated) within a cell.

[0120] Typically, the AAV *rep/cap* sequences will not be flanked by the AAV packaging sequences (e.g., AAV ITRs), to prevent rescue and/or packaging of these sequences.

[0121] The template (e.g., an rAAV vector genome) can be provided to the cell using any method known in the art. For example, the template may be supplied by a non-viral (e.g., plasmid) or viral vector. In particular embodiments, the template is supplied by a herpesvirus or adenovirus vector (e.g., inserted into the E1a or E3 regions of a deleted adenovirus). As another illustration, Palombo et al., (1998) J. Virol. 72:5025, describe a baculovirus vector carrying a reporter gene flanked by the AAV ITRs. EBV vectors may also be employed to deliver the template, as described above with respect to the *rep/cap* genes.

[0122] In another representative embodiment, the template is provided by a replicating rAAV virus. In still other embodiments, an AAV provirus is stably integrated into the chromosome of the cell.

[0123] To obtain maximal virus titers, helper virus functions (e.g., adenovirus or herpesvirus) essential for a productive AAV infection are generally provided to the cell. Helper virus sequences necessary for AAV replication are known in the art. Typically, these sequences are provided by a helper adenovirus or herpesvirus vector. Alternatively, the adenovirus or herpesvirus sequences can be provided by another non-viral or viral vector, e.g., as a non-infectious adenovirus miniplasmid that carries all of the helper genes required for efficient AAV production as described by Ferrari et al., (1997) Nature Med. 3:1295, and U.S. Patent Nos. 6,040,183 and 6,093,570.

[0124] Further, the helper virus functions may be provided by a packaging cell with the helper genes integrated in the chromosome or maintained as a stable extrachromosomal element. In representative embodiments, the helper virus sequences cannot be packaged into AAV virions, e.g., are not flanked by AAV ITRs.

[0125] Those skilled in the art will appreciate that it may be advantageous to provide the AAV replication and capsid sequences and the helper virus sequences (e.g., adenovirus sequences) on a single helper construct. This helper construct may be a non-viral or viral construct, but is optionally a hybrid adenovirus or hybrid herpesvirus comprising the AAV *rep/cap* genes.

[0126] In one particular embodiment, the AAV *rep/cap* sequences and the adenovirus helper sequences are supplied by a single adenovirus helper vector. This vector further contains the rAAV template. The AAV *rep/cap* sequences and/or the rAAV template may be inserted into a deleted region (e.g., the E1a or E3 regions) of the adenovirus.

[0127] In a further embodiment, the AAV *rep/cap* sequences and the adenovirus helper sequences are supplied by a single adenovirus helper vector. The rAAV template is provided as a plasmid template.

[0128] In another illustrative embodiment, the AAV *rep/cap* sequences and adenovirus helper sequences are provided by a single adenovirus helper vector, and the rAAV template is integrated into the cell as a provirus. Alternatively, the rAAV template is provided by an EBV vector that is maintained within the cell as an extrachromosomal element (e.g., as a "EBV based nuclear episome," see Margolski, (1992) Curr. Top. Microbiol. Immun. 158:67).

[0129] In a further exemplary embodiment, the AAV *rep/cap* sequences and adenovirus helper sequences are provided by a single adenovirus helper. The rAAV template is provided as a separate replicating viral vector. For example, the rAAV template may be provided by a rAAV particle or a second recombinant adenovirus particle.

[0130] According to the foregoing methods, the hybrid adenovirus vector typically comprises the adenovirus 5' and 3' *cis* sequences sufficient for adenovirus replication and packaging (i.e., the adenovirus terminal repeats and PAC sequence). The AAV *rep/cap* sequences and, if present, the rAAV template are embedded in the adenovirus backbone and are flanked by the 5' and 3' *cis* sequences, so that these sequences may be packaged into adenovirus capsids. As described above, in representative embodiments, the adenovirus helper sequences and the AAV *rep/cap* sequences are not flanked by the AAV packaging sequences (e.g., the AAV ITRs), so that these sequences are not packaged into the AAV virions.

[0131] Herpesvirus may also be used as a helper virus in AAV packaging methods. Hybrid herpesviruses encoding the AAV *rep* protein(s) may advantageously facilitate for more scalable AAV vector production schemes. A hybrid herpes

simplex virus type I (HSV-1) vector expressing the AAV-2 *rep* and *cap* genes has been described (Conway et al., (1999) Gene Therapy 6:986 and WO 00/17377).

[0132] As a further alternative, the virus vectors of the invention can be produced in insect cells using baculovirus vectors to deliver the *rep/cap* genes and rAAV template as described by Urabe et al., (2002) Human Gene Therapy 13:1935-43.

[0133] Other methods of producing AAV use stably transformed packaging cells (see, e.g., U.S. Patent No. 5,658,785).

[0134] AAV vector stocks free of contaminating helper virus may be obtained by any method known in the art. For example, AAV and helper virus may be readily differentiated based on size. AAV may also be separated away from helper virus based on affinity for a heparin substrate (Zolotukhin et al., (1999) Gene Therapy 6:973). In representative embodiments, deleted replication-defective helper viruses are used so that any contaminating helper virus is not replication competent. As a further alternative, an adenovirus helper lacking late gene expression may be employed, as only adenovirus early gene expression is required to mediate packaging of AAV virus. Adenovirus mutants defective for late gene expression are known in the art (e.g., ts100K and ts149 adenovirus mutants).

[0135] The inventive packaging methods may be employed to produce high titer stocks of virus particles. In particular embodiments, the virus stock has a titer of at least about 10^5 transducing units (tu)/ml, at least about 10^6 tu/ml, at least about 10^7 tu/ml, at least about 10^8 tu/ml, at least about 10^9 tu/ml, or at least about 10^{10} tu/ml.

[0136] The novel capsid protein and capsid structures find use in raising antibodies, for example, for diagnostic or therapeutic uses or as a research reagent. Thus, the invention also provides antibodies against the novel capsid proteins and capsids of the invention.

[0137] The term "antibody" or "antibodies" as used herein refers to all types of immunoglobulins, including IgG, IgM, IgA, IgD, and IgE. The antibody can be monoclonal or polyclonal and can be of any species of origin, including (for example) mouse, rat, rabbit, horse, goat, sheep or human, or can be a chimeric antibody. See, e.g., Walker et al., Mol. Immunol. 26, 403-11 (1989). The antibodies can be recombinant monoclonal antibodies, for example, produced according to the methods disclosed in U.S. Patent No. 4,474,893 or U.S. Patent No. 4,816,567. The antibodies can also be chemically constructed, for example, according to the method disclosed in U.S. Patent No. 4,676,980.

[0138] Antibody fragments included within the scope of the present invention include, for example, Fab, F(ab')₂, and Fc fragments, and the corresponding fragments obtained from antibodies other than IgG. Such fragments can be produced by known techniques. For example, F(ab')₂ fragments can be produced by pepsin digestion of the antibody molecule, and Fab fragments can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries can be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse et al., (1989) Science 254, 1275-1281).

[0139] Polyclonal antibodies can be produced by immunizing a suitable animal (e.g., rabbit, goat, etc.) with an antigen to which a monoclonal antibody to the target binds, collecting immune serum from the animal, and separating the polyclonal antibodies from the immune serum, in accordance with known procedures.

[0140] Monoclonal antibodies can be produced in a hybridoma cell line according to the technique of Kohler and Milstein, (1975) Nature 265, 495-97. For example, a solution containing the appropriate antigen can be injected into a mouse and, after a sufficient time, the mouse sacrificed and spleen cells obtained. The spleen cells are then immortalized by fusing them with myeloma cells or with lymphoma cells, typically in the presence of polyethylene glycol, to produce hybridoma cells. The hybridoma cells are then grown in a suitable medium and the supernatant screened for monoclonal antibodies having the desired specificity. Monoclonal Fab fragments can be produced in *E. coli* by recombinant techniques known to those skilled in the art. See, e.g., W. Huse, (1989) Science 246, 1275-81.

[0141] Antibodies specific to a target polypeptide can also be obtained by phage display techniques known in the art.

[0142] Various immunoassays can be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificity are well known in the art. Such immunoassays typically involve the measurement of complex formation between an antigen and its specific antibody (e.g., antigen/antibody complex formation). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes can be used as well as a competitive binding assay.

[0143] Antibodies can be conjugated to a solid support (e.g., beads, plates, slides or wells formed from materials such as latex or polystyrene) in accordance with known techniques. Antibodies can likewise be directly or indirectly conjugated to detectable groups such as radiolabels (e.g., ³⁵S, ¹²⁵I, ¹³¹I), enzyme labels (e.g., horseradish peroxidase, alkaline phosphatase), and fluorescence labels (e.g., fluorescein) in accordance with known techniques. Determination of the formation of an antibody/antigen complex in the methods of this invention can be by detection of, for example, precipitation, agglutination, flocculation, radioactivity, color development or change, fluorescence, luminescence, etc., as is well known in the art.

III. Methods of Using Chimeric AAV Capsids.

[0144] The present invention also relates to methods for delivering heterologous nucleotide sequences into oligodendrocytes. The virus vectors of the invention may be employed, *e.g.*, to deliver a nucleotide sequence of interest to an oligodendrocyte *in vitro*, *e.g.*, to produce a polypeptide or nucleic acid *in vitro* or for *ex vivo* gene therapy. The vectors are additionally useful in a method of delivering a nucleotide sequence to a subject in need thereof, *e.g.*, to express a therapeutic or immunogenic polypeptide or nucleic acid. In this manner, the polypeptide or nucleic acid may thus be produced *in vivo* in the subject. The subject may be in need of the polypeptide or nucleic acid because the subject has a deficiency of the polypeptide, or because the production of the polypeptide or nucleic acid in the subject may impart some therapeutic effect, as a method of treatment or otherwise, and as explained further below.

[0145] In particular embodiments, the vectors are useful to express a polypeptide or nucleic acid that provides a beneficial effect to oligodendrocytes, *e.g.*, to promote growth and/or differentiation of oligodendrocytes. The ability to target vectors to oligodendrocytes may be particularly useful to treat diseases or disorders involving oligodendrocyte dysfunction and/or demyelination of neurons. In other embodiments, the vectors are useful to express a polypeptide or nucleic acid that provides a beneficial effect to cells near the oligodendrocytes (*e.g.*, neurons).

[0146] Thus, one aspect of the invention relates to a method of delivering a nucleic acid of interest to an oligodendrocyte, the method comprising contacting the oligodendrocyte with the AAV particle of the invention.

[0147] In another aspect, the invention relates to a method of delivering a nucleic acid of interest to an oligodendrocyte in a mammalian subject, the method comprising administering an effective amount of the AAV particle or pharmaceutical formulation of the invention to a mammalian subject.

[0148] A further aspect of the invention relates to a method of treating a disorder associated with oligodendrocyte dysfunction in a subject in need thereof, the method comprising administering a therapeutically effective amount of the AAV particle of the invention to the subject. In one embodiment, the disorder associated with oligodendrocyte dysfunction is a demyelinating disease. In one embodiment, the disorder associated with oligodendrocyte dysfunction is multiple sclerosis, Pelizaeus-Merzbacher disease, Krabbe's disease, metachromatic leukodystrophy, adrenoleukodystrophy, Canavan disease, Alexander disease, orthochromatic leukodystrophy, Zellweger disease, 18q-syndrome, cerebral palsy, spinal cord injury, traumatic brain injury, stroke, phenylketonuria, or viral infection, or any other disorder known or later found to be associated with oligodendrocyte dysfunction. In another embodiment, the methods of the invention are used to treat a disorder that is not directly associated with oligodendrocyte dysfunction but would benefit by expression of a heterologous polypeptide or nucleic acid in oligodendrocytes in addition to or instead of expression in neurons, astrocytes, or other CNS cell types. Examples include, without limitation, neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, CNS tumors, and other CNS disorders.

[0149] CNS disorders include but are not limited to disorders of thinking and cognition such as schizophrenia and delirium; amnesic disorders; disorders of mood, such as affective disorders and anxiety disorders (including post-traumatic stress disorder, separation anxiety disorder, selective mutism, reactive attachment disorder, stereotypic movement disorder, panic disorders, agoraphobia, specific phobias, social phobia, obsessive-compulsive disorder, acute stress disorder, generalized anxiety disorder, substance-induced anxiety disorder and/or anxiety disorder not otherwise specified); disorders of social behavior; disorders of learning and memory, such as learning disorders (*e.g.*, dyslexia); motor skills disorders; communication disorders (*e.g.*, stuttering); pervasive developmental disorders (*e.g.*, autistic disorder, Rett's disorder, childhood disintegrative disorder, Asperger's disorder, and/or pervasive developmental disorder not otherwise specified) and dementia. Accordingly, the term "central nervous system disorder" encompasses the disorders listed above as well as depressive disorders (including major depressive disorder, dysthymic disorder, depressive disorder not otherwise specified, postpartum depression); seasonal affective disorder; mania; bipolar disorders (including bipolar I disorder, bipolar II disorder, cyclothymic disorder, bipolar disorder not otherwise specified); attention-deficit and disruptive behavior disorders (including attention deficit disorder with hyperactivity disorder, conduct disorder, oppositional defiant disorder and/or disruptive behavior disorder not otherwise specified); drug addiction/substance abuse (including abuse of opiates, amphetamines, alcohol, hallucinogens, cannabis, inhalants, phencyclidine, sedatives, hypnotics, anxiolytics and/or cocaine); alcohol-induced disorders; amphetamine-induced disorders; caffeine-induced disorders; cannabis-induced disorders; cocaine-induced disorders; hallucinogen-induced disorders; inhalant-induced disorders; nicotine-induced disorders; opioid-induced disorders; phencyclidine-induced disorders; sedative, hypnotic or anxiolytic-induced disorders; agitation; apathy; psychoses; irritability; disinhibition; schizophreniform disorder; schizoaffective disorder; delusional disorder; brief psychotic disorder, shared psychotic disorder; substance-induced psychotic disorder; psychotic disorder not otherwise specified; unipolar disorders, mood disorders (*e.g.*, mood disorder with psychotic features); somatoform disorders; factitious disorders; disassociative disorders; mental retardation; feeding and eating disorders of infancy or early childhood; eating disorders such as anorexia nervosa, bulimia nervosa and/or eating disorder not otherwise specified; sleeping disorders (*e.g.*, dyssomnias such as primary insomnia, primary hypersomnia, narcolepsy, breathing-related sleep disorder and circadian rhythm sleep disorder and/or parasomnias); impulse control disorders (*e.g.*, kleptomania, pyromania, trichotillomania, pathological gambling and/or intermittent explosive disorder);

adjustment disorders; personality disorders (e.g., paranoid personality disorder, schizoid personality disorder, schizotypal personality disorder, antisocial personality disorder, borderline personality disorder, histrionic personality disorder, narcissistic personality disorder, avoidant personality disorder, dependent personality disorder and/or obsessive-compulsive personality disorder); Tic disorders (e.g., Tourette's disorder, chronic motor or vocal tic disorder, transient tic disorder and/or tic disorder not otherwise specified); elimination disorders; and any combination of the foregoing as well as any other disorder or group of disorders described in the Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV; the American Psychiatric Association, Washington D.C., 1994). "Central Nervous System disorders" also include other conditions that implicate the CNS including but not limited to neurodegenerative disorders such as Alzheimer's disease, involuntary movement disorders such as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and the like. Other CNS disorders include without limitation epilepsy, multiple sclerosis, neurogenic pain, psychogenic pain, and migraines. In other embodiments, the CNS disorder encompasses any subset of the foregoing diseases or excludes any one or more of the foregoing conditions. In particular embodiments, the term "central nervous system disorder" does not encompass benign and/or malignant tumors of the CNS.

[0150] In another aspect of the invention, the chimeric AAV capsid and vectors of the invention are fully- or nearly fully-detargeted vectors that can be further modified to a desirable tropic profile for targeting of one or more peripheral organs or tissues as discussed below. In this aspect, the present invention also relates to methods for delivering heterologous nucleotide sequences into a broad range of cells, including dividing and non-dividing cells. The virus vectors of the invention may be employed to deliver a nucleotide sequence of interest to a cell *in vitro*, e.g., to produce a polypeptide *in vitro* or for *ex vivo* gene therapy. The vectors are additionally useful in a method of delivering a nucleotide sequence to a subject in need thereof, e.g., to express a therapeutic or immunogenic polypeptide or nucleic acid. In this manner, the polypeptide or nucleic acid may thus be produced *in vivo* in the subject. The subject may be in need of the polypeptide or nucleic acid because the subject has a deficiency of the polypeptide, or because the production of the polypeptide or nucleic acid in the subject may impart some therapeutic effect, as a method of treatment or otherwise, and as explained further below.

[0151] In general, the virus vectors of the invention may be employed to deliver any foreign nucleic acid with a biological effect to treat or ameliorate the symptoms associated with any disorder related to gene expression. Further, the invention can be used to treat any disease state for which it is beneficial to deliver a therapeutic polypeptide. Illustrative disease states include, but are not limited to: cystic fibrosis (cystic fibrosis transmembrane regulator protein) and other diseases of the lung, hemophilia A (Factor VIII), hemophilia B (Factor IX), thalassemia (β -globin), anemia (erythropoietin) and other blood disorders, Alzheimer's disease (GDF; neprilysin), multiple sclerosis (β -interferon), Parkinson's disease (glial-cell line derived neurotrophic factor [GDNF]), Huntington's disease (inhibitory RNA including without limitation RNAi such as siRNA or shRNA, antisense RNA or microRNA to remove repeats), amyotrophic lateral sclerosis, epilepsy (galanin, neurotrophic factors), and other neurological disorders, cancer (endostatin, angiostatin, TRAIL, FAS-ligand, cytokines including interferons; inhibitory RNA including without limitation RNAi (such as siRNA or shRNA), antisense RNA and microRNA including inhibitory RNA against VEGF, the multiple drug resistance gene product or a cancer immunogen), diabetes mellitus (insulin, PGC- α 1, GLP-1, myostatin pro-peptide, glucose transporter 4), muscular dystrophies including Duchenne and Becker (e.g., dystrophin, mini-dystrophin, micro-dystrophin, insulin-like growth factor I, a sarcoglycan [e.g., α , β , γ]), Inhibitory RNA [e.g., RNAi, antisense RNA or microRNA] against myostatin or myostatin propeptide, laminin-alpha2, Fukutin-related protein, dominant negative myostatin, follistatin, activin type II soluble receptor, anti-inflammatory polypeptides such as the Ikappa B dominant mutant, sarcospan, utrophin, mini-utrophin, inhibitory RNA [e.g., RNAi, antisense RNA or microRNA] against splice junctions in the dystrophin gene to induce exon skipping [see, e.g., WO/2003/095647], inhibitory RNA (e.g., RNAi, antisense RNA or micro RNA) against U7 snRNAs to induce exon skipping [see, e.g., WO/2006/021724], and antibodies or antibody fragments against myostatin or myostatin propeptide), Gaucher disease (glucocerebrosidase), Hurler's disease (α -L-iduronidase), adenosine deaminase deficiency (adenosine deaminase), glycogen storage diseases (e.g., Fabry disease [α -galactosidase] and Pompe disease [lysosomal acid α -glucosidase]) and other metabolic defects including other lysosomal storage disorders and glycogen storage disorders, congenital emphysema (α 1-antitrypsin), Lesch-Nyhan Syndrome (hypoxanthine guanine phosphoribosyl transferase), Niemann-Pick disease (sphingomyelinase), Maple Syrup Urine Disease (branched-chain keto acid dehydrogenase), retinal degenerative diseases (and other diseases of the eye and retina; e.g., PDGF, endostatin and/or angiostatin for macular degeneration), diseases of solid organs such as brain (including Parkinson's Disease [GDNF], astrocytomas [endostatin, angiostatin and/or RNAi against VEGF], glioblastomas [endostatin, angiostatin and/or RNAi against VEGF]), liver (RNAi such as siRNA or shRNA, microRNA or antisense RNA for hepatitis B and/or hepatitis C genes), kidney, heart including congestive heart failure or peripheral artery disease (PAD) (e.g., by delivering protein phosphatase inhibitor I [I-1], phospholamban, sarcoplasmic endoreticulum Ca^{2+} -ATPase [serca2a], zinc finger proteins that regulate the phospholamban gene, Pim-1, PGC-1 α , SOD-1, SOD-2, ECF-SOD, kallikrein, thymosin- β 4, hypoxia-inducible transcription factor [HIF], Barkct, β 2-adrenergic receptor, β 2-adrenergic receptor kinase [β ARK], phosphoinositide-3 kinase [PI3 kinase], calsarcin, an angiogenic factor, S100A1, parvalbumin, adenylyl cyclase type 6, a molecule that effects G-protein coupled receptor kinase type 2 knockdown such as a truncated constitutively active bARKct, an

inhibitory RNA [e.g., RNAi, antisense RNA or microRNA] against phospholamban; phospholamban inhibitory or dominant-negative molecules such as phospholamban S16E, etc.), arthritis (insulin-like growth factors), joint disorders (insulin-like growth factors), intimal hyperplasia (e.g., by delivering enos, inos), improve survival of heart transplants (superoxide dismutase), AIDS (soluble CD4), muscle wasting (insulin-like growth factor I, myostatin pro-peptide, an anti-apoptotic factor, follistatin), limb ischemia (VEGF, FGF, PGC-1 α , EC-SOD, HIF), kidney deficiency (erythropoietin), anemia (erythropoietin), arthritis (anti-inflammatory factors such as IRAP and TNF α soluble receptor), hepatitis (α -interferon), LDL receptor deficiency (LDL receptor), hyperammonemia (ornithine transcarbamylase), spinal cerebral ataxias including SCA1, SCA2 and SCA3, phenylketonuria (phenylalanine hydroxylase), autoimmune diseases, and the like. The invention can further be used following organ transplantation to increase the success of the transplant and/or to reduce the negative side effects of organ transplantation or adjunct therapies (e.g., by administering immunosuppressant agents or inhibitory nucleic acids to block cytokine production). As another example, bone morphogenic proteins (including RANKL and/or VEGF) can be administered with a bone allograft, for example, following a break or surgical removal in a cancer patient.

[0152] Exemplary lysosomal storage diseases that can be treated according to the present invention include without limitation: Hurler's Syndrome (MPS IH), Scheie's Syndrome (MPS IS), and Hurler-Scheie Syndrome (MPS IH/S) (α -L-iduronidase); Hunter's Syndrome (MPS II) (iduronate sulfate sulfatase); Sanfilippo A Syndrome (MPS IIIA) (Heparan-S-sulfate sulfaminidase), Sanfilippo B Syndrome (MPS IIIB) (*N*-acetyl-D-glucosaminidase), Sanfilippo C Syndrome (MPS IIIC) (Acetyl-CoA-glucosaminide *N*-acetyltransferase), Sanfilippo D Syndrome (MPS IIID) (*N*-acetyl-glucosaminine-6-sulfate sulfatase); Morquio A disease (MPS IVA) (Galactosamine-6-sulfate sulfatase), Morquio B disease (MPS IV B) (β -Galactosidase); Maroteaux-Lmay disease (MPS VI) (arylsulfatase B); Sly Syndrome (MPS VII) (β -glucuronidase); hyaluronidase deficiency (MPS IX) (hyaluronidase); sialidosis (mucopolidosis I), mucopolidosis II (I-Cell disease) (*N*-acetylglucos-aminyl-1-phosphotransferase catalytic subunit), mucopolidosis III (pseudo-Hurler polydystrophy) (*N*-acetylglucos-aminyl-1-phosphotransferase; type IIIA [catalytic subunit] and type IIIC [substrate recognition subunit]); GM1 gangliosidosis (ganglioside β -galactosidase), GM2 gangliosidosis Type I (Tay-Sachs disease) (β -hexaminidase A), GM2 gangliosidosis type II (Sandhoff's disease) (β -hexosaminidase B); Niemann-Pick disease (Types A and B) (sphingomyelinase); Gaucher's disease (glucocerebrosidase); Farber's disease (ceramidase); Fabry's disease (α -galactosidase A); Krabbe's disease (galactosylceramide β -galactosidase); metachromatic leukodystrophy (arylsulfatase A); lysosomal acid lipase deficiency including Wolman's disease (lysosomal acid lipase); Batten disease (juvenile neuronal ceroid lipofuscinosis) (lysosomal transmembrane CLN3 protein) sialidosis (neuraminidase 1); galactosialidosis (Goldberg's syndrome) (protective protein/ cathepsin A); α -mannosidosis (α -D-mannosidase); β -mannosidosis (β -D-mannosidosis); fucosidosis (α -D-fucosidase); aspartylglucosaminuria (*N*-Aspartylglucosaminidase); and sialuria (Na phosphate cotransporter).

[0153] Exemplary glycogen storage diseases that can be treated according to the present invention include, but are not limited to, Type Ia GSD (von Gierke disease) (glucose-6-phosphatase), Type Ib GSD (glucose-6-phosphate translocase), Type Ic GSD (microsomal phosphate or pyrophosphate transporter), Type Id GSD (microsomal glucose transporter), Type II GSD including Pompe disease or infantile Type IIa GSD (lysosomal acid α -glucosidase) and Type IIb (Danon) (lysosomal membrane protein-2), Type IIIa and IIIb GSD (Debrancher enzyme; amyloglucosidase and oligoglucanotransferase), Type IV GSD (Andersen's disease) (branching enzyme), Type V GSD (McArdle disease) (muscle phosphorylase), Type VI GSD (Hers' disease) (liver phosphorylase), Type VII GSD (Tarui's disease) (phosphofructokinase), GSD Type VIII/IXa (X-linked phosphorylase kinase), GSD Type IXb (Liver and muscle phosphorylase kinase), GSD Type IXc (liver phosphorylase kinase), GSD Type IXd (muscle phosphorylase kinase), GSD O (glycogen synthase), Fanconi-Bickel syndrome (glucose transporter-2), phosphoglucosomerase deficiency, muscle phosphoglycerate kinase deficiency, phosphoglycerate mutase deficiency, fructose 1,6-diphosphatase deficiency, phosphoenolpyruvate carboxykinase deficiency, and lactate dehydrogenase deficiency.

[0154] Nucleic acids and polypeptides that can be delivered to cardiac muscle include those that are beneficial in the treatment of damaged, degenerated or atrophied cardiac muscle and/or congenital cardiac defects. For example, angiogenic factors useful for facilitating vascularization in the treatment of heart disease include but are not limited to vascular endothelial growth factor (VEGF), VEGF II, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF₁₂₁, VEGF₁₃₈, VEGF₁₄₅, VEGF₁₆₅, VEGF₁₈₉, VEGF₂₀₆, hypoxia inducible factor 1 α (HIF 1 α), endothelial NO synthase (eNOS), iNOS, VEGFR-1 (Flt1), VEGFR-2 (KDR/Flk1), VEGFR-3 (Flt4), angiogenin, epidermal growth factor (EGF), angiopoietin, platelet-derived growth factor, angiogenic factor, transforming growth factor- α (TGF- α), transforming growth factor- β (TGF- β), vascular permeability factor (VPF), tumor necrosis factor alpha (TNF- α), interleukin-3 (IL-3), interleukin-8 (IL-8), platelet-derived endothelial growth factor (PD-EGF), granulocyte colony stimulating factor (G-CSF), hepatocyte growth factor (HGF), scatter factor (SF), pleiotrophin, proliferin, follistatin, placental growth factor (PIGF), midkine, platelet-derived growth factor-BB (PDGF), fractalkine, ICAM-1, angiopoietin-1 and -2 (Ang1 and Ang2), Tie-2, neuropilin-1, ICAM-1, chemokines and cytokines that stimulate smooth muscle cell, monocyte, or leukocyte migration, anti-apoptotic peptides and proteins, fibroblast growth factors (FGF), FGF-1, FGF-1b, FGF-1c, FGF-2, FGF-2b, FGF-2c, FGF-3, FGF-3b, FGF-3c, FGF-4, FGF-5, FGF-7, FGF-9, acidic FGF, basic FGF, monocyte chemotactic protein-1, granulocyte macrophage-colony stimulating factor, insulin-like growth factor-1 (IGF-1), IGF-2, early growth response factor-1 (EGR-1), ETS-1, human tissue

kallikrein (HK), matrix metalloproteinase, chymase, urokinase-type plasminogen activator and heparinase. (see, e.g., U.S. Patent Application No. 20060287259 and U.S. Patent Application No. 20070059288).

[0155] The most common congenital heart disease found in adults is bicuspid aortic valve, whereas atrial septal defect is responsible for 30-40% of congenital heart disease seen in adults. The most common congenital cardiac defect observed in the pediatric population is ventricular septal defect. Other congenital heart diseases include Eisenmenger's syndrome, patent ductus arteriosus, pulmonary stenosis, coarctation of the aorta, transposition of the great arteries, tricuspid atresia, univentricular heart, Ebstein's anomaly, and double-outlet right ventricle. A number of studies have identified putative genetic loci associated with one or more of these congenital heart diseases. For example, the putative gene(s) for congenital heart disease associated with Down syndrome is 21q22.2-q22.3, between ETS2 and MX1. Similarly, most cases of DiGeorge syndrome result from a deletion of chromosome 22q1.2 (the DiGeorge syndrome chromosome region, or DGCR). Several genes are lost in this deletion including the putative transcription factor TUPLE1. This deletion is associated with a variety of phenotypes, e.g., Shprintzen syndrome; conotruncal anomaly face (or Takao syndrome); and isolated outflow tract defects of the heart including Tetralogy of Fallot, truncus arteriosus, and interrupted aortic arch. All of the foregoing disorders can be treated according to the present invention.

[0156] Other significant diseases of the heart and vascular system are also believed to have a genetic, typically polygenic, etiological component. These diseases include, for example, hypoplastic left heart syndrome, cardiac valvular dysplasia, Pfeiffer cardiocranial syndrome, oculofaciocardiodental syndrome, Kapur-Toriello syndrome, Sonoda syndrome, Ohdo Blepharophimosis syndrome, heart-hand syndrome, Pierre-Robin syndrome, Hirschsprung disease, Kousseff syndrome, Grange occlusive arterial syndrome, Kearns-Sayre syndrome, Kartagener syndrome, Alagille syndrome, Ritscher-Schinzel syndrome, Ivemark syndrome, Young-Simpson syndrome, hemochromatosis, Holzgreve syndrome, Barth syndrome, Smith-Lemli-Opitz syndrome, glycogen storage disease, Gaucher-like disease, Fabry disease, Lowry-Maclean syndrome, Rett syndrome, Opitz syndrome, Marfan syndrome, Miller-Dieker lissencephaly syndrome, mucopolysaccharidosis, Bruada syndrome, humerospinal dysostosis, Phaver syndrome, McDonough syndrome, Marfanoid hypermobility syndrome, atransferrinemia, Cornelia de Lange syndrome, Leopard syndrome, Diamond-Blackfan anemia, Steinfeld syndrome, progeria, and Williams-Beuren syndrome. All of these disorders can be treated according to the present invention.

[0157] Anti-apoptotic factors can be delivered to skeletal muscle, diaphragm muscle and/or cardiac muscle to treat muscle wasting diseases, limb ischemia, cardiac infarction, heart failure, coronary artery disease and/or type I or type II diabetes.

[0158] Nucleic acids that can be delivered to skeletal muscle include those that are beneficial in the treatment of damaged, degenerated and/or atrophied skeletal muscle. The genetic defects that cause muscular dystrophy are known for many forms of the disease. These defective genes either fail to produce a protein product, produce a protein product that fails to function properly, or produce a dysfunctional protein product that interferes with the proper function of the cell. The heterologous nucleic acid may encode a therapeutically functional protein or a polynucleotide that inhibits production or activity of a dysfunctional protein. Polypeptides that may be expressed from delivered nucleic acids, or inhibited by delivered nucleic acids (e.g., by delivering RNAi, microRNA or antisense RNA), include without limitation dystrophin, a mini-dystrophin or a micro-dystrophin (Duchene's and Becker MD); dystrophin-associated glycoproteins β -sarcoglycan (limb-girdle MD 2E), δ -sarcoglycan (limb-girdle MD 2 2F), α -sarcoglycan (limb girdle MD 2D) and γ -sarcoglycan (limb-girdle MD 2C), utrophin, calpain (autosomal recessive limb-girdle MD type 2A), caveolin-3 (autosomal-dominant limb-girdle MD), laminin-alpha2 (merosin-deficient congenital MD), miniagrin (laminin-alpha2 deficient congenital MD), fukutin (Fukuyama type congenital MD), emerin (Emery-Dreifuss MD), myotilin, lamin A/C, calpain-3, dysferlin, and/or telethonin. Further, the heterologous nucleic acid can encode mir-1, mir-133, mir-206, mir-208 or an antisense RNA, RNAi (e.g., siRNA or shRNA) or microRNA to induce exon skipping in a defective dystrophin gene.

[0159] In particular embodiments, the nucleic acid is delivered to tongue muscle (e.g., to treat dystrophic tongue). Methods of delivering to the tongue can be by any method known in the art including direct injection, oral administration, topical administration to the tongue, intravenous administration, intra-articular administration and the like.

[0160] The foregoing proteins can also be administered to diaphragm muscle to treat muscular dystrophy.

[0161] Alternatively, a gene transfer vector may be administered that encodes any other therapeutic polypeptide.

[0162] In particular embodiments, a virus vector according to the present invention is used to deliver a nucleic acid of interest as described herein to skeletal muscle, diaphragm muscle and/or cardiac muscle, for example, to treat a disorder associated with one or more of these tissues such as muscular dystrophy, heart disease (including PAD and congestive heart failure), and the like.

[0163] Gene transfer has substantial potential use in understanding and providing therapy for disease states. There are a number of inherited diseases in which defective genes are known and have been cloned. In general, the above disease states fall into two classes: deficiency states, usually of enzymes, which are generally inherited in a recessive manner, and unbalanced states, which may involve regulatory or structural proteins, and which are typically inherited in a dominant manner. For deficiency state diseases, gene transfer can be used to bring a normal gene into affected tissues for replacement therapy, as well as to create animal models for the disease using inhibitory RNA such as RNAi

(e.g., siRNA or shRNA), microRNA or antisense RNA. For unbalanced disease states, gene transfer can be used to create a disease state in a model system, which can then be used in efforts to counteract the disease state. Thus, the virus vectors according to the present invention permit the treatment of genetic diseases. As used herein, a disease state is treated by partially or wholly remedying the deficiency or imbalance that causes the disease or makes it more severe. The use of site-specific recombination of nucleic sequences to cause mutations or to correct defects is also possible.

[0164] The virus vectors according to the present invention may also be employed to provide an antisense nucleic acid or inhibitory RNA (e.g., microRNA or RNAi such as a siRNA or shRNA) to a cell *in vitro* or *in vivo*. Expression of the inhibitory RNA in the target cell diminishes expression of a particular protein(s) by the cell. Accordingly, inhibitory RNA may be administered to decrease expression of a particular protein in a subject in need thereof. Inhibitory RNA may also be administered to cells *in vitro* to regulate cell physiology, e.g., to optimize cell or tissue culture systems.

[0165] As a further aspect, the virus vectors of the present invention may be used to produce an immune response in a subject. According to this embodiment, a virus vector comprising a nucleic acid encoding an immunogen may be administered to a subject, and an active immune response (optionally, a protective immune response) is mounted by the subject against the immunogen. Immunogens are as described hereinabove.

[0166] Alternatively, the virus vector may be administered to a cell *ex vivo* and the altered cell is administered to the subject. The heterologous nucleic acid is introduced into the cell, and the cell is administered to the subject, where the heterologous nucleic acid encoding the immunogen is optionally expressed and induces an immune response in the subject against the immunogen. In particular embodiments, the cell is an antigen-presenting cell (e.g., a dendritic cell).

[0167] An "active immune response" or "active immunity" is characterized by "participation of host tissues and cells after an encounter with the immunogen. It involves differentiation and proliferation of immunocompetent cells in lymphoreticular tissues, which lead to synthesis of antibody or the development of cell-mediated reactivity, or both." Herbert B. Hershowitz, Immunophysiology: Cell Function and Cellular Interactions in Antibody Formation, in IMMUNOLOGY: BASIC PROCESSES 117 (Joseph A. Bellanti ed., 1985). Alternatively stated, an active immune response is mounted by the host after exposure to immunogens by infection or by vaccination. Active immunity can be contrasted with passive immunity, which is acquired through the "transfer of preformed substances (antibody, transfer factor, thymic graft, interleukin-2) from an actively immunized host to a non-immune host." *Id.*

[0168] A "protective" immune response or "protective" immunity as used herein indicates that the immune response confers some benefit to the subject in that it prevents or reduces the incidence of disease. Alternatively, a protective immune response or protective immunity may be useful in the treatment of disease, in particular cancer or tumors (e.g., by causing regression of a cancer or tumor and/or by preventing metastasis and/or by preventing growth of metastatic nodules). The protective effects may be complete or partial, as long as the benefits of the treatment outweigh any disadvantages thereof.

[0169] The virus vectors of the present invention may also be administered for cancer immunotherapy by administration of a viral vector expressing a cancer cell antigen (or an immunologically similar molecule) or any other immunogen that produces an immune response against a cancer cell. To illustrate, an immune response may be produced against a cancer cell antigen in a subject by administering a viral vector comprising a heterologous nucleotide sequence encoding the cancer cell antigen, for example to treat a patient with cancer. The virus vector may be administered to a subject *in vivo* or by using *ex vivo* methods, as described herein.

[0170] As used herein, the term "cancer" encompasses tumor-forming cancers. Likewise, the term "cancerous tissue" encompasses tumors. A "cancer cell antigen" encompasses tumor antigens.

[0171] The term "cancer" has its understood meaning in the art, for example, an uncontrolled growth of tissue that has the potential to spread to distant sites of the body (*i.e.*, metastasize). Exemplary cancers include, but are not limited to, leukemia, lymphoma (e.g., Hodgkin and non-Hodgkin lymphomas), colorectal cancer, renal cancer, liver cancer, breast cancer, lung cancer, prostate cancer, testicular cancer, ovarian cancer, uterine cancer, cervical cancer, brain cancer (e.g., gliomas and glioblastoma), bone cancer, sarcoma, melanoma, head and neck cancer, esophageal cancer, thyroid cancer, and the like. In embodiments of the invention, the invention is practiced to treat and/or prevent tumor-forming cancers.

[0172] The term "tumor" is also understood in the art, for example, as an abnormal mass of undifferentiated cells within a multicellular organism. Tumors can be malignant or benign. In representative embodiments, the methods disclosed herein are used to prevent and treat malignant tumors.

[0173] Cancer cell antigens have been described hereinabove. By the terms "treating cancer" or "treatment of cancer," it is intended that the severity of the cancer is reduced or the cancer is prevented or at least partially eliminated. For example, in particular contexts, these terms indicate that metastasis of the cancer is prevented or reduced or at least partially eliminated. In further representative embodiments, these terms indicate that growth of metastatic nodules (e.g., after surgical removal of a primary tumor) is prevented or reduced or at least partially eliminated. By the terms "prevention of cancer" or "preventing cancer" it is intended that the methods at least partially eliminate or reduce the incidence or onset of cancer. Alternatively stated, the onset or progression of cancer in the subject may be slowed, controlled,

decreased in likelihood or probability, or delayed.

[0174] In particular embodiments, cells may be removed from a subject with cancer and contacted with a virus vector according to the present invention. The modified cell is then administered to the subject, whereby an immune response against the cancer cell antigen is elicited. This method is particularly advantageously employed with immunocompromised subjects that cannot mount a sufficient immune response *in vivo* (*i.e.*, cannot produce enhancing antibodies in sufficient quantities).

[0175] It is known in the art that immune responses may be enhanced by immunomodulatory cytokines (*e.g.*, α -interferon, β -interferon, γ -interferon, ω -interferon, τ -interferon, interleukin-1 α , interleukin-1 β , interleukin-2, interleukin-3, interleukin-4, interleukin 5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin 12, interleukin-13, interleukin-14, interleukin-18, B cell Growth factor, CD40 Ligand, tumor necrosis factor- α , tumor necrosis factor- β , monocyte chemoattractant protein-1, granulocyte-macrophage colony stimulating factor, and lymphotoxin). Accordingly, immunomodulatory cytokines (*e.g.*, CTL inductive cytokines) may be administered to a subject in conjunction with the virus vectors.

[0176] Cytokines may be administered by any method known in the art. Exogenous cytokines may be administered to the subject, or alternatively, a nucleotide sequence encoding a cytokine may be delivered to the subject using a suitable vector, and the cytokine produced *in vivo*.

[0177] The viral vectors are further useful for targeting oligodendrocytes for research purposes, *e.g.*, for study of CNS function *in vitro* or in animals or for use in creating and/or studying animal models of disease. For example, the vectors can be used to deliver heterologous nucleic acids to oligodendrocytes in animal models of demyelinating diseases. Demyelination can be induced in animals by a variety of means, including without limitation administration of viruses (*e.g.*, Semliki virus, murine hepatitis virus, or Theiler's murine encephalomyelitis virus) and administration of chemicals (*e.g.*, cuprizone, ethidium bromide, or lyssolecithin). In some embodiments, the vector can also be used in animal models of experimental autoimmune encephalomyelitis. This condition can be induced by, for example, administration of kainite, SIN-1, anti-galactocerebroside, or irradiation. In other embodiments, the viral vector can be used to specifically deliver to oligodendrocytes a toxic agent or an enzyme that produces a toxic agent (*e.g.*, thymidine kinase) in order to kill some or all of the cells.

[0178] Further, the virus vectors according to the present invention find further use in diagnostic and screening methods, whereby a gene of interest is transiently or stably expressed in a cell culture system, or alternatively, a transgenic animal model. The invention can also be practiced to deliver a nucleic acid for the purposes of protein production, *e.g.*, for laboratory, industrial or commercial purposes.

[0179] Recombinant virus vectors according to the present invention find use in both veterinary and medical applications. Suitable subjects include both avians and mammals. The term "avian" as used herein includes, but is not limited to, chickens, ducks, geese, quail, turkeys, pheasant, parrots, parakeets. The term "mammal" as used herein includes, but is not limited to, humans, primates non-human primates (*e.g.*, monkeys and baboons), cattle, sheep, goats, pigs, horses, cats, dogs, rabbits, rodents (*e.g.*, rats, mice, hamsters, and the like), *etc.* Human subjects include neonates, infants, juveniles, and adults. Optionally, the subject is "in need of" the methods of the present invention, *e.g.*, because the subject has or is believed at risk for a disorder including those described herein or that would benefit from the delivery of a nucleic acid including those described herein. For example, in particular embodiments, the subject has (or has had) or is at risk for a demyelinating disorder or a spinal cord or brain injury. As a further option, the subject can be a laboratory animal and/or an animal model of disease.

[0180] In particular embodiments, the present invention provides a pharmaceutical composition comprising a virus vector of the invention in a pharmaceutically acceptable carrier and, optionally, other medicinal agents, pharmaceutical agents, stabilizing agents, buffers, carriers, adjuvants, diluents, *etc.* For injection, the carrier will typically be a liquid. For other methods of administration, the carrier may be either solid or liquid. For inhalation administration, the carrier will be respirable, and will preferably be in solid or liquid particulate form.

[0181] By "pharmaceutically acceptable" it is meant a material that is not toxic or otherwise undesirable, *i.e.*, the material may be administered to a subject without causing any undesirable biological effects.

[0182] One aspect of the present invention is a method of transferring a nucleotide sequence to a cell *in vitro*. The virus vector may be introduced to the cells at the appropriate multiplicity of infection according to standard transduction methods appropriate for the particular target cells. Titers of the virus vector or capsid to administer can vary, depending upon the target cell type and number, and the particular virus vector or capsid, and can be determined by those of skill in the art without undue experimentation. In particular embodiments, at least about 10^3 infectious units, more preferably at least about 10^5 infectious units are introduced to the cell.

[0183] The cell(s) into which the virus vector can be introduced may be of any type, including but not limited to neural cells (including cells of the peripheral and central nervous systems, in particular, brain cells such as neurons, oligodendrocytes, glial cells, astrocytes), lung cells, cells of the eye (including retinal cells, retinal pigment epithelium, and corneal cells), epithelial cells (*e.g.*, gut and respiratory epithelial cells), skeletal muscle cells (including myoblasts, myotubes and myofibers), diaphragm muscle cells, dendritic cells, pancreatic cells (including islet cells), hepatic cells, a cell of the

gastrointestinal tract (including smooth muscle cells, epithelial cells), heart cells (including cardiomyocytes), bone cells (e.g., bone marrow stem cells), hematopoietic stem cells, spleen cells, keratinocytes, fibroblasts, endothelial cells, prostate cells, joint cells (including, e.g., cartilage, meniscus, synovium and bone marrow), germ cells, and the like. Alternatively, the cell may be any progenitor cell. As a further alternative, the cell can be a stem cell (e.g., neural stem cell, liver stem cell). As still a further alternative, the cell may be a cancer or tumor cell (cancers and tumors are described above). Moreover, the cells can be from any species of origin, as indicated above.

[0184] The virus vectors may be introduced to cells *in vitro* for the purpose of administering the modified cell to a subject. In particular embodiments, the cells have been removed from a subject, the virus vector is introduced therein, and the cells are then replaced back into the subject. Methods of removing cells from subject for treatment *ex vivo*, followed by introduction back into the subject are known in the art (see, e.g., U.S. patent No. 5,399,346). Alternatively, the recombinant virus vector is introduced into cells from another subject, into cultured cells, or into cells from any other suitable source, and the cells are administered to a subject in need thereof.

[0185] Suitable cells for *ex vivo* gene therapy are as described above. Dosages of the cells to administer to a subject will vary upon the age, condition and species of the subject, the type of cell, the nucleic acid being expressed by the cell, the mode of administration, and the like. Typically, at least about 10^2 to about 10^8 or about 10^3 to about 10^6 cells will be administered per dose in a pharmaceutically acceptable carrier. In particular embodiments, the cells transduced with the virus vector are administered to the subject in an effective amount in combination with a pharmaceutical carrier.

[0186] In some embodiments, cells that have been transduced with the virus vector may be administered to elicit an immunogenic response against the delivered polypeptide (e.g., expressed as a transgene or in the capsid). Typically, a quantity of cells expressing an effective amount of the polypeptide in combination with a pharmaceutically acceptable carrier is administered. Optionally, the dosage is sufficient to produce a protective immune response (as defined above). The degree of protection conferred need not be complete or permanent, as long as the benefits of administering the immunogenic polypeptide outweigh any disadvantages thereof.

[0187] A further aspect of the invention is a method of administering the virus vectors or capsids of the invention to subjects. In particular embodiments, the method comprises a method of delivering a nucleic acid of interest to an animal subject, the method comprising: administering an effective amount of a virus vector according to the invention to an animal subject. Administration of the virus vectors of the present invention to a human subject or an animal in need thereof can be by any means known in the art. Optionally, the virus vector is delivered in an effective dose in a pharmaceutically acceptable carrier.

[0188] The virus vectors of the invention can further be administered to a subject to elicit an immunogenic response (e.g., as a vaccine). Typically, vaccines of the present invention comprise an effective amount of virus in combination with a pharmaceutically acceptable carrier. Optionally, the dosage is sufficient to produce a protective immune response (as defined above). The degree of protection conferred need not be complete or permanent, as long as the benefits of administering the immunogenic polypeptide outweigh any disadvantages thereof. Subjects and immunogens are as described above.

[0189] Dosages of the virus vectors to be administered to a subject will depend upon the mode of administration, the disease or condition to be treated, the individual subject's condition, the particular virus vector, and the nucleic acid to be delivered, and can be determined in a routine manner. Exemplary doses for achieving therapeutic effects are virus titers of at least about 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} , 10^{11} , 10^{12} , 10^3 , 10^{14} , 10^{15} transducing units or more, preferably about 10^7 or 10^8 , 10^9 , 10^{10} , 10^{11} , 10^{12} , 10^{13} or 10^{14} transducing units, yet more preferably about 10^{12} transducing units.

[0190] In particular embodiments, more than one administration (e.g., two, three, four or more administrations) may be employed to achieve the desired level of gene expression over a period of various intervals, e.g., daily, weekly, monthly, yearly, etc.

[0191] Exemplary modes of administration include oral, rectal, transmucosal, topical, intranasal, inhalation (e.g., via an aerosol), buccal (e.g., sublingual), vaginal, intrathecal, intraocular, transdermal, *in utero* (or *in ovo*), parenteral (e.g., intravenous, subcutaneous, intradermal, intramuscular [including administration to skeletal, diaphragm and/or cardiac muscle], intradermal, intrapleural, intracerebral, and intraarticular), topical (e.g., to both skin and mucosal surfaces, including airway surfaces, and transdermal administration), intro-lymphatic, and the like, as well as direct tissue or organ injection (e.g., to liver, skeletal muscle, cardiac muscle, diaphragm muscle or brain). Administration can also be to a tumor (e.g., in or near a tumor or a lymph node). The most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular vector that is being used.

[0192] In some embodiments, the viral vector is administered directly to the CNS, e.g., the brain or the spinal cord. Direct administration can result in high specificity of transduction of oligodendrocytes, e.g., wherein at least 80%, 85%, 90%, 95% or more of the transduced cells are oligodendrocytes. Any method known in the art to administer vectors directly to the CNS can be used. The vector may be introduced into the spinal cord, brainstem (medulla oblongata, pons), midbrain (hypothalamus, thalamus, epithalamus, pituitary gland, substantia nigra, pineal gland), cerebellum, telencephalon (corpus striatum, cerebrum including the occipital, temporal, parietal and frontal lobes, cortex, basal ganglia, hippocampus and amygdala), limbic system, neocortex, corpus striatum, cerebrum, and inferior colliculus. The

vector may also be administered to different regions of the eye such as the retina, cornea or optic nerve. The vector may be delivered into the cerebrospinal fluid (e.g., by lumbar puncture) for more disperse administration of the vector.

[0193] The delivery vector may be administered to the desired region(s) of the CNS by any route known in the art, including but not limited to, intrathecal, intracerebral, intraventricular, intranasal, intra-aural, intra-ocular (e.g., intra-vitreous, sub-retinal, anterior chamber) and peri-ocular (e.g., sub-Tenon's region) delivery or any combination thereof.

[0194] Typically, the viral vector will be administered in a liquid formulation by direct injection (e.g., stereotactic injection) to the desired region or compartment in the CNS. In some embodiments, the vector can be delivered via a reservoir and/or pump. In other embodiments, the vector may be provided by topical application to the desired region or by intranasal administration of an aerosol formulation. Administration to the eye or into the ear, may be by topical application of liquid droplets. As a further alternative, the vector may be administered as a solid, slow-release formulation. Controlled release of parvovirus and AAV vectors is described by international patent publication WO 01/91803.

[0195] In some embodiments where the subject has a compromised blood-brain barrier (BBB), the viral vector can be delivered systemically (e.g., intravenously) to the subject, wherein the vector transduces oligodendrocytes in the area of (e.g., bordering) the BBB compromise. In certain embodiments, the vector transduces cells in the compromised area but not cells in uncompromised areas. Thus, one aspect of the invention relates to a method of delivering a nucleic acid of interest to an area of the CNS bordering a compromised blood brain barrier area in a mammalian subject, the method comprising intravenously administering an effective amount of the AAV particle of the invention.

[0196] In some embodiments, the compromise in the BBB is due to a disease or disorder. Examples include, without limitation, neurodegenerative diseases such as Alzheimer's, Parkinson's disease, disease, amyotrophic lateral sclerosis, and multiple sclerosis, epilepsy, CNS tumors, or cerebral infarcts. In other embodiments, the BBB compromise can be an induced disruption, e.g., to promote delivery of agents to the CNS. Temporary BBB compromises can be induced by, for example, toxic chemicals (such as metrazol, VP-16, cisplatin, hydroxyurea, fluorouracil, and etoposide), osmotic agents (such as mannitol and arabinose), biological agents (such as retinoic acid, phorbol myristate acetate, leukotriene C4, bradykinin, histamine, RMP-7, and alkylglycerols), or irradiation (such as ultrasound or electromagnetic radiation).

[0197] Administration to skeletal muscle according to the present invention includes but is not limited to administration to skeletal muscles in the limbs (e.g., upper arm, lower arm, upper leg, and/or lower leg), back, neck, head (e.g., tongue), thorax, abdomen, pelvis/perineum, and/or digits. Suitable skeletal muscle tissues include but are not limited to abductor digiti minimi (in the hand), abductor digiti minimi (in the foot), abductor hallucis, abductor ossis metatarsi quinti, abductor pollicis brevis, abductor pollicis longus, adductor brevis, adductor hallucis, adductor longus, adductor magnus, adductor pollicis, anconeus, anterior scalene, articularis genus, biceps brachii, biceps femoris, brachialis, brachioradialis, buccinator, coracobrachialis, corrugator supercilii, deltoid, depressor anguli oris, depressor labii inferioris, digastric, dorsal interossei (in the hand), dorsal interossei (in the foot), extensor carpi radialis brevis, extensor carpi radialis longus, extensor carpi ulnaris, extensor digiti minimi, extensor digitorum, extensor digitorum brevis, extensor digitorum longus, extensor hallucis brevis, extensor hallucis longus, extensor indicis, extensor pollicis brevis, extensor pollicis longus, flexor carpi radialis, flexor carpi ulnaris, flexor digiti minimi brevis (in the hand), flexor digiti minimi brevis (in the foot), flexor digitorum brevis, flexor digitorum longus, flexor digitorum profundus, flexor digitorum superficialis, flexor hallucis brevis, flexor hallucis longus, flexor pollicis brevis, flexor pollicis longus, frontalis, gastrocnemius, geniohyoid, gluteus maximus, gluteus medius, gluteus minimus, gracilis, iliocostalis cervicis, iliocostalis lumborum, iliocostalis thoracis, iliocostalis, inferior gemellus, inferior oblique, inferior rectus, infrapinnatus, interspinalis, intertransversi, lateral pterygoid, lateral rectus, latissimus dorsi, levator anguli oris, levator labii superioris, levator labii superioris alaeque nasi, levator palpebrae superioris, levator scapulae, long rotators, longissimus capitis, longissimus cervicis, longissimus thoracis, longus capitis, longus colli, lumbricals (in the hand), lumbricals (in the foot), masseter, medial pterygoid, medial rectus, middle scalene, multifidus, mylohyoid, obliquus capitis inferior, obliquus capitis superior, obturator externus, obturator internus, occipitalis, omohyoid, opponens digiti minimi, opponens pollicis, orbicularis oculi, orbicularis oris, palmar interossei, palmaris brevis, palmaris longus, pectineus, pectoralis major, pectoralis minor, peroneus brevis, peroneus longus, peroneus tertius, piriformis, plantar interossei, plantaris, platysma, popliteus, posterior scalene, pronator quadratus, pronator teres, psoas major, quadratus femoris, quadratus plantae, rectus capitis anterior, rectus capitis lateralis, rectus capitis posterior major, rectus capitis posterior minor, rectus femoris, rhomboid major, rhomboid minor, risorius, sartorius, scalenus minimus, semimembranosus, semispinalis capitis, semispinalis cervicis, semispinalis thoracis, semitendinosus, serratus anterior, short rotators, soleus, spinalis capitis, spinalis cervicis, spinalis thoracis, splenius capitis, splenius cervicis, sternocleidomastoid, sternohyoid, sternothyroid, stylohyoid, subclavius, subscapularis, superior gemellus, superior oblique, superior rectus, supinator, supraspinatus, temporalis, tensor fascia lata, teres major, teres minor, thoracis, thyrohyoid, tibialis anterior, tibialis posterior, trapezius, triceps brachii, vastus intermedius, vastus lateralis, vastus medialis, zygomaticus major, and zygomaticus minor and any other suitable skeletal muscle as known in the art.

[0198] The virus vector can be delivered to skeletal muscle by any suitable method including without limitation intravenous administration, intra-arterial administration, intraperitoneal administration, isolated limb perfusion (of leg and/or arm; see, e.g. Arruda et al., (2005) Blood 105:3458-3464), and/or direct intramuscular injection.

[0199] Administration to cardiac muscle includes without limitation administration to the left atrium, right atrium, left

ventricle, right ventricle and/or septum. The virus vector can be delivered to cardiac muscle by any method known in the art including, e.g., intravenous administration, intra-arterial administration such as intra-aortic administration, direct cardiac injection (e.g., into left atrium, right atrium, left ventricle, right ventricle), and/or coronary artery perfusion.

[0200] Administration to diaphragm muscle can be by any suitable method including intravenous administration, intra-arterial administration, and/or intraperitoneal administration.

[0201] Delivery to any of these tissues can also be achieved by delivering a depot comprising the virus vector, which can be implanted into the skeletal, cardiac and/or diaphragm muscle tissue or the tissue can be contacted with a film or other matrix comprising the virus vector. Examples of such implantable matrices or substrates are described in U.S. Patent No. 7,201,898.

[0202] In particular embodiments, a virus vector according to the present invention is administered to skeletal muscle, diaphragm muscle and/or cardiac muscle (e.g., to treat muscular dystrophy or heart disease [for example, PAD or congestive heart failure]).

[0203] The invention can be used to treat disorders of skeletal, cardiac and/or diaphragm muscle. Alternatively, the invention can be practiced to deliver a nucleic acid to skeletal, cardiac and/or diaphragm muscle, which is used as a platform for production of a protein product (e.g., an enzyme) or non-translated RNA (e.g., RNAi, microRNA, antisense RNA) that normally circulates in the blood or for systemic delivery to other tissues to treat a disorder (e.g., a metabolic disorder, such as diabetes (e.g., insulin), hemophilia (e.g., Factor IX or Factor VIII), or a lysosomal storage disorder (such as Gaucher's disease [glucocerebrosidase], Pompe disease [lysosomal acid α -glucosidase] or Fabry disease [α -galactosidase A]) or a glycogen storage disorder (such as Pompe disease [lysosomal acid α -glucosidase])). Other suitable proteins for treating metabolic disorders are described above.

[0204] In a representative embodiment, the invention provides a method of treating muscular dystrophy in a subject in need thereof, the method comprising: administering an effective amount of a virus vector of the invention to a mammalian subject, wherein the virus vector comprises a heterologous nucleic acid effective to treat muscular dystrophy. In an exemplary embodiment, the method comprises: administering an effective amount of a virus vector of the invention to a mammalian subject, wherein the virus vector comprises a heterologous nucleic acid encoding dystrophin, a mini-dystrophin, a micro-dystrophin, utrophin, mini-utrophin, laminin- α 2, mini-agrin, Fukutin-related protein, follistatin, dominant negative myostatin, α -sarcoglycan, β -sarcoglycan, γ -sarcoglycan, δ -sarcoglycan, IGF-1, myostatin propeptide, activin type II soluble receptor, anti-inflammatory polypeptides such as the Ikappa B dominant mutant, sarcospan, antibodies or antibody fragments against myostatin or myostatin propeptide, or an inhibitory RNA (e.g., antisense RNA, microRNA or RNAi) against myostatin, mir-1, mir-133, mir-206, mir-208 or an inhibitory RNA (e.g., microRNA, RNAi or antisense RNA) to induce exon skipping in a defective dystrophin gene. In particular embodiments, the virus vector can be administered to skeletal, diaphragm and/or cardiac muscle as described elsewhere herein.

[0205] The invention further encompasses a method of treating a metabolic disorder in a subject in need thereof. In representative embodiments, the method comprises: administering an effective amount of a virus vector of the invention to skeletal muscle of a subject, wherein the virus vector comprises a heterologous nucleic acid encoding a polypeptide, wherein the metabolic disorder is a result of a deficiency and/or defect in the polypeptide. Illustrative metabolic disorders and heterologous nucleic acids encoding polypeptides are described herein. As a further option, the heterologous nucleic acid can encode a secreted protein.

The invention can also be practiced to produce inhibitory RNA (e.g., antisense RNA, microRNA or RNAi) for systemic delivery.

[0206] The invention also provides a method of treating congenital heart failure in a subject in need thereof, the method comprising administering an effective amount of a virus vector of the invention to a mammalian subject, wherein the virus vector comprises a heterologous nucleic acid effective to treat congenital heart failure. In representative embodiments, the method comprises administering an effective amount of a virus vector of the invention to a mammalian subject, wherein the virus vector comprises a heterologous nucleic acid encoding a sarcoplasmic endoreticulum Ca^{2+} -ATPase (SERCA2a), an angiogenic factor, phospholamban, PI3 kinase, calsarcin, a β -adrenergic receptor kinase (β ARK), β ARKct, inhibitor 1 of protein phosphatase 1, Pim-1, PGC-1 α , SOD-1, SOD-2, EC-SOD, Kallikrein, HIF, thymosin- β 4, S100A1, parvalbumin, adenylyl cyclase type 6, a molecule that effects G-protein coupled receptor kinase type 2 knock-down such as a truncated constitutively active β ARKct; phospholamban inhibitory or dominant-negative molecules such as phospholamban S16E, mir-1, mir-133, mir-206, mir-208.

[0207] Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Alternatively, one may administer the virus vector in a local rather than systemic manner, for example, in a depot or sustained-release formulation. Further, the virus vector can be delivered dried to a surgically implantable matrix such as a bone graft substitute, a suture, a stent, and the like (e.g., as described in U.S. Patent 7,201,898).

[0208] Pharmaceutical compositions suitable for oral administration can be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of the composition of this invention; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-

in-oil emulsion. Oral delivery can be performed by complexing a virus vector of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers include plastic capsules or tablets, as known in the art. Such formulations are prepared by any suitable method of pharmacy, which includes the step of bringing into association the composition and a suitable carrier (which may contain one or more accessory ingredients as noted above). In general, the pharmaceutical composition according to embodiments of the present invention are prepared by uniformly and intimately admixing the composition with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the resulting mixture. For example, a tablet can be prepared by compressing or molding a powder or granules containing the composition, optionally with one or more accessory ingredients. Compressed tablets are prepared by compressing, in a suitable machine, the composition in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, and/or surface active/dispersing agent(s). Molded tablets are made by molding, in a suitable machine, the powdered compound moistened with an inert liquid binder.

[0209] Pharmaceutical compositions suitable for buccal (sub-lingual) administration include lozenges comprising the composition of this invention in a flavored base, usually sucrose and acacia or tragacanth; and pastilles comprising the composition in an inert base such as gelatin and glycerin or sucrose and acacia.

[0210] Pharmaceutical compositions suitable for parenteral administration can comprise sterile aqueous and non-aqueous injection solutions of the composition of this invention, which preparations are optionally isotonic with the blood of the intended recipient. These preparations can contain anti-oxidants, buffers, bacteriostats and solutes, which render the composition isotonic with the blood of the intended recipient. Aqueous and non-aqueous sterile suspensions, solutions and emulsions can include suspending agents and thickening agents. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, anti-microbials, anti-oxidants, chelating agents, and inert gases and the like.

[0211] The compositions can be presented in unit/dose or multi-dose containers, for example, in sealed ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or water-for-injection immediately prior to use.

[0212] Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules and tablets of the kind previously described. For example, an injectable, stable, sterile composition of this invention in a unit dosage form in a sealed container can be provided. The composition can be provided in the form of a lyophilizate, which can be reconstituted with a suitable pharmaceutically acceptable carrier to form a liquid composition suitable for injection into a subject. The unit dosage form can be from about 1 μ g to about 10 grams of the composition of this invention. When the composition is substantially water-insoluble, a sufficient amount of emulsifying agent, which is physiologically acceptable, can be included in sufficient quantity to emulsify the composition in an aqueous carrier. One such useful emulsifying agent is phosphatidyl choline.

[0213] Pharmaceutical compositions suitable for rectal administration can be presented as unit dose suppositories. These can be prepared by admixing the composition with one or more conventional solid carriers, such as for example, cocoa butter and then shaping the resulting mixture.

[0214] Pharmaceutical compositions of this invention suitable for topical application to the skin can take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, and/or oil. Carriers that can be used include, but are not limited to, petroleum jelly, lanoline, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof. In some embodiments, for example, topical delivery can be performed by mixing a pharmaceutical composition of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

[0215] Pharmaceutical compositions suitable for transdermal administration can be in the form of discrete patches adapted to remain in intimate contact with the epidermis of the subject for a prolonged period of time. Compositions suitable for transdermal administration can also be delivered by iontophoresis (see, for example, Pharm. Res. 3:318 (1986)) and typically take the form of an optionally buffered aqueous solution of the composition of this invention. Suitable formulations can comprise citrate or bis/tris buffer (pH 6) or ethanol/water and can contain from 0.1 to 0.2M active ingredient.

[0216] The virus vectors disclosed herein may be administered to the lungs of a subject by any suitable means, for example, by administering an aerosol suspension of respirable particles comprised of the virus vectors, which the subject inhales. The respirable particles may be liquid or solid. Aerosols of liquid particles comprising the virus vectors may be produced by any suitable means, such as with a pressure-driven aerosol nebulizer or an ultrasonic nebulizer, as is known to those of skill in the art. See, e.g., U.S. Patent No. 4,501,729. Aerosols of solid particles comprising the virus vectors may likewise be produced with any solid particulate medicament aerosol generator, by techniques known in the pharmaceutical art.

IV. Use of the AAV Capsid to Target Peripheral Tissues.

[0217] The AAV capsids and vectors of the present invention have been demonstrated to be fully or nearly fully detargeted for peripheral organs and tissues (see Fig. 4). This detargeting makes the vectors ideal as a "blank" vector that can be altered to produce the desired tropic profile, e.g., to target specific organs and tissues and/or detarget other organs and tissues. Thus, one aspect of the invention relates to a method of preparing an AAV capsid having a tropism profile of interest, the method comprising modifying the AAV capsid of the present invention to insert an amino acid sequence providing the tropism profile of interest. In some embodiments, the tropism profile of interest is enhanced selectivity for a tissue selected from skeletal muscle, cardiac muscle, diaphragm, kidney, liver, pancreas, spleen, gastrointestinal tract, lung, joint tissue, tongue, ovary, testis, a germ cell, a cancer cell, or a combination thereof and/or reduced selectivity for a tissue selected from liver, ovary, testis, a germ cell, or a combination thereof.

[0218] Examples of specific targeting and detargeting sequences are known in the art. One example is the molecular basis for preferential liver tropism, which has been mapped, in the case of AAV2 and AAV6, to a continuous basic footprint that appears to be involved in the interaction of either serotype with heparin. Specifically, it has previously been demonstrated that a single lysine residue on AAV6 (K531) dictates heparin binding ability and consequently, liver tropism. In corollary, substitutional mutagenesis of the corresponding glutamate/aspartate residue on other serotypes with a lysine residue confers heparin binding, possibly by forming a minimum continuous basic footprint on the capsid surface. Another example is the capsid mutants comprising alterations in the three-fold axis loop 4 as disclosed in International Publication No. WO 2012/093784. These mutants exhibit one or more properties including (i) reduced transduction of liver, (ii) enhanced movement across endothelial cells, (iii) systemic transduction; (iv) enhanced transduction of muscle tissue (e.g., skeletal muscle, cardiac muscle and/or diaphragm muscle), and/or (v) reduced transduction of brain tissues (e.g., neurons). Other tropic sequences are described in Li et al., (2012) J. Virol. 86:7752-7759; Pulicherla et al., (2011) Mol. Ther. 19:1070-1078; Bowles et al., (2012) Mol. Ther. 20:443-455; Asokan et al., (2012) Mol. Ther. 20:699-708; and Asokan et al., (2010) Nature Biotechnol. 28:79-82.

[0219] In some embodiments, the AAV capsid of the present invention can be modified through DNA scrambling and/or directed evolution to identify modified capsids having the desired tropism profile. Techniques for DNA scrambling and directed evolution of AAV capsids are described in International Publication No. WO 2009/137006.

[0220] Having described the present invention, the same will be explained in greater detail in the following examples, which are included herein for illustration purposes only, and which are not intended to be limiting to the invention.

EXAMPLE 1

Discovery and Characterization of the BNP61 AAV Clone

[0221] A mutant DNA shuffled AAV capsid library was injected intravenously into a rat model of Parkinson's disease and 3 days later cells were dissociated from the caudate nucleus. Using PCR rescue, a single clone emerged (BNP61). Additional shuffling and selection yielded the same clone. As seen in Fig. 1, this clone is a chimera of several AAV serotypes.

[0222] Direct infusion of this BNP61 clone into the rat brain produced a surprising cellular transduction pattern. To date, almost all diverse AAV serotypes and chimeras exhibit a >95% tropism for neurons, when gene expression is driven by a constitutive promoter. In marked contrast, BNP61 exhibited a >95% tropism for oligodendrocytes with no evidence of astrocyte or microglial transduction and minimal neuronal transduction (Figs. 2A-2C). Fig. 2A shows GFP positive oligodendrocytes in the rat caudate 1 week after the infusion of BNP61-CBh-GFP vectors. Note that there are no GFP positive neurons. Fig. 2B shows a higher magnification that reflects clear oligodendrocyte morphology, and Fig. 2C shows that none of the GFP positive cells colocalize with the cellular marker for astrocytes, GFAP (red).

[0223] Also, in primary oligodendrocyte cultures, BNP61 transduces the oligodendrocytes but not the underlying bed of astrocytes (Figs. 3A-3B). Mixed glial cultures at day 10 were transduced with BNP61-GFP at a MOI of 100 viral particles and images were taken 72 hr later. Fig. 3A is a light image of the glial culture. Fig. 3B is an image of fluorescent AAV GFP-positive cells taken from the same frame as Fig. 3A. The underlayer bed of astrocytes was not transduced and nearly all GFP-expressing cells appear morphologically as oligodendrocytes. Arrows indicate near-focused oligodendrocytes showing processes consistent with oligodendrocyte progenitor culture morphology. Thus, the BNP61 AAV vector exhibits properties that are distinctly different from other AAV vectors characterized to date.

[0224] In order to assess peripheral biodistribution, mice received intravenous administration of BNP61-CBh-GFP vectors and subsequently the peripheral organs were harvested. All mice were injected as adults with 5×10^{10} vg except as indicated. Neonatal injections were with 2.5×10^{10} vg. Adults were sacrificed 10 days post-injection, and neonates were sacrificed at 4 weeks post-injection. * indicates samples not tested. In the legend, the number of animals for each vector is shown in parentheses. Error bars are S.E.M. As seen in Fig. 4, BNP61 did not accumulate in any of the peripheral organs.

EXAMPLE 2**BNP61 Crosses the Compromised Blood-Brain Barrier**

[0225] After the first selection round, the BNP61 clone was packaged with GFP and recombinant virus was produced. Then, 2 weeks post-6-OHDA treatment the recombinant virus was administered intravenously at a dose of 8×10^{11} vector genomes/kg. One month later, the rats were sacrificed, and the brains sectioned. In these 2-week post treatment rats, substantial gene expression was found in oligodendrocytes and some neurons within the 6-OHDA treated striatum (Fig. 5), while no gene expression was found in the contralateral striatum, the injector tract in the cortex or distal brain structures. Note the lack of NeuN co-localization with the many oligodendrocytes that surround the lone NeuN positive neuron (Fig. 5). Thus, it appears that after intravenous administration this novel AAV clone exhibits the ability to cross the 6-OHDA compromised blood-brain barrier, but not the intact blood-brain barrier.

EXAMPLE 3**Generation of Additional Oligodendrocyte Targeted Clones**

[0226] Using the same AAV DNA capsid shuffling and in vivo directed evolution process described in Example 1, two additional oligodendrocyte-targeted clones were identified, BNP62 and BNP63. As shown in Fig. 1 and similar to BNP61, these clones are chimeras of several AAV serotypes. The amino acid sequence identity between the three clones is shown in Table 2. All three clones are greater than 95% identical to each other at the amino acid level.

Table 2: Sequence identity between clones

	BNP61	BNP62	BNP63
BNP61	100%	96%	97%
BNP62	96%	100%	96%
BNP63	97%	96%	100%

[0227] Fig. 6 shows that the BNP63 clone transduces oligodendrocytes in the rat piriform cortex. The BNP63 transduced cells (green) do not co-localize with a cellular marker for astrocytes (GFAP, red). Also, the transduced cells exhibit a clear oligodendrocyte morphology.

Itemized list of embodiments**[0228]**

1. A nucleic acid encoding an AAV capsid, the nucleic acid comprising an AAV capsid coding sequence that is at least 90% identical to:

(a) the nucleotide sequence of SEQ ID NO: 1; or

(b) a nucleotide sequence encoding one of SEQ ID NOS:2-4.

2. The nucleic acid of in item 1, wherein the AAV capsid coding sequence is at least 95% identical to the nucleotide sequence of (a) or (b).

3. The nucleic acid of item 1, wherein the AAV capsid coding sequence comprises the nucleotide sequence of (a) or (b).

4. The nucleic acid of any one of items 1-3, wherein the nucleic acid is a plasmid, phage, viral vector, bacterial artificial chromosome, or yeast artificial chromosome.

5. The nucleic acid of any one of items 1-4, wherein the nucleic acid is an AAV vector comprising the coding sequence.

6. The nucleic acid of any one of items 1-5, wherein the nucleic acid further comprises an AAV rep coding sequence.

7. A cell *in vitro* comprising the nucleic acid of any one of items 1-6 stably incorporated into the genome.

8. A virus particle comprising the nucleic acid of any one of items 1-6.

9. The virus particle of item 8, wherein the virus particle is an AAV particle, an adenovirus particle, a herpesvirus particle, or a baculovirus particle.

10. An AAV capsid comprising an amino acid sequence at least 96% identical to one of SEQ ID NOS:2-4.

11. The AAV capsid of item 10, comprising an amino acid sequence at least 99% identical to one of SEQ ID NOS:2-4.

12. The AAV capsid of item 10, comprising the amino acid sequence of one of SEQ ID NOS:2-4.

13. The AAV capsid of any one of items 10-12 covalently linked, bound to, or encapsidating a compound selected from the group consisting of a DNA molecule, an RNA molecule, a polypeptide, a carbohydrate, a lipid, and a small organic molecule.

14. An AAV particle comprising:

an AAV vector genome; and

the AAV capsid of any one of items 10-12, wherein the AAV capsid encapsidates the AAV vector genome.

15. The AAV particle of item 14, wherein the AAV vector genome comprises a heterologous nucleic acid.

16. The AAV particle of item 14, wherein the heterologous nucleic acid encodes an antisense RNA, microRNA, or RNAi.

17. The AAV particle of item 14, wherein the heterologous nucleic acid encodes a polypeptide.

18. The AAV particle of item 17, wherein the heterologous nucleic acid encodes a therapeutic polypeptide.

19. The AAV particle of item 17, wherein the heterologous nucleic acid encodes a growth factor or differentiation factor.

20. The AAV particle of item 17, wherein the heterologous nucleic acid encodes insulin growth factor-1, glial-derived neurotrophic factor, neurotrophin-3, artemin, transforming growth factor alpha, platelet-derived growth factor, leukemia inhibitory factor, prolactin, monocarboxylate transporter 1, or nuclear factor 1A.

21. The AAV particle of item 17, wherein the heterologous nucleic acid encodes a reporter protein.

22. The AAV particle of any one of items 15-21, wherein the heterologous nucleic acid is operably linked to a constitutive promoter.

23. The AAV particle of any one of items 15-21, wherein the heterologous nucleic acid is operably linked to an oligodendrocyte-specific or oligodendrocyte-preferred promoter.

24. The AAV particle of item 23, wherein the oligodendrocyte-specific or oligodendrocyte-preferred promoter is a promoter selected from myelin basic protein, cyclic nucleotide phosphodiesterase, proteolipid protein, Gtx, or Sox10.

25. A method of producing a recombinant AAV particle comprising an AAV capsid, the method comprising:

- providing a cell *in vitro* with a nucleic acid according to any one of items 1-6, an AAV rep coding sequence, an AAV vector genome comprising a heterologous nucleic acid, and helper functions for generating a productive AAV infection; and

- allowing assembly of the recombinant AAV particle comprising the AAV capsid and encapsidating the AAV vector genome.

26. An AAV particle produced by the method of item 25.

27. A pharmaceutical formulation comprising the nucleic acid of any one of items 1-6, the virus particle of any one of items 8 or 9, the AAV capsid of any one of items 10-13, or the AAV particle of any one of items 14-24 or 26 in a pharmaceutically acceptable carrier.

28. A method of delivering a nucleic acid of interest to an oligodendrocyte, the method comprising contacting the oligodendrocyte with the AAV particle of any one of items 14-24 or 26.

29. A method of delivering a nucleic acid of interest to an oligodendrocyte in a mammalian subject, the method comprising:
administering an effective amount of the AAV particle of any one of items 14-24 or 26 or the pharmaceutical formulation of item 27 to a mammalian subject.

30. The method of item 29, wherein the mammalian subject is a human subject.

31. The method of item 29 or 30, wherein the AAV particle is delivered to the central nervous system (CNS).

32. The method of item 31, wherein the AAV particle is delivered directly to the CNS by intrathecal, intracerebral, intraventricular, intranasal, intra-aural, intra-ocular, or peri-ocular delivery, or any combination thereof.

33. The method of item 31, wherein the subject has a compromised blood brain barrier and the AAV particle is delivered to the CNS by intravenous administration.

34. A method of delivering a nucleic acid of interest to an area of the CNS bordering a compromised blood brain barrier area in a mammalian subject, the method comprising:
intravenously administering an effective amount of the AAV particle of any one of items 14-24 or 26 or the pharmaceutical formulation of item 27 to a mammalian subject.

35. A method of treating a disorder associated with oligodendrocyte dysfunction in a mammalian subject in need thereof, the method comprising administering a therapeutically effective amount of the AAV particle of any one of items 14-24 or 26 or the pharmaceutical formulation of item 27 to a mammalian subject.

36. The method of item 35, wherein the disorder associated with oligodendrocyte dysfunction is a demyelinating disease.

37. The method of item 35, wherein the disorder associated with oligodendrocyte dysfunction is multiple sclerosis, Pelizaeus-Merzbacher disease, Krabbe's disease, metachromatic leukodystrophy, adrenoleukodystrophy, Canavan disease, Alexander disease, orthochromatic leukodystrophy, Zellweger disease, 18q-syndrome, cerebral palsy, spinal cord injury, traumatic brain injury, stroke, phenylketonuria, or viral infection.

38. A method of preparing an AAV capsid having a tropism profile of interest, the method comprising modifying the AAV capsid of any one of items 10-12 to insert an amino acid sequence providing the tropism profile of interest.

39. The method of item 38, wherein the tropism profile of interest is a tissue selected from skeletal muscle, liver, cardiac muscle, diaphragm, kidney, liver, pancreas, spleen, gastrointestinal tract, lung, joint tissue, tongue, ovary, testis, a germ cell, a cancer cell, or a combination thereof.

EP 3 738 974 A1

SEQUENCE LISTING

5 <110> University of North Carolina at Chapel Hill
 Thomas, McCown
 Gray, Steven

<120> AAV VECTORS TARGETED TOWARD OLIGODENDROCYTES

<130> 5470-637WO

10 <150> US 61/707,108
 <151> 2012-09-28

<160> 4

15 <170> PatentIn version 3.5

<210> 1
 <211> 2214
 <212> DNA
 <213> Artificial

20 <220>
 <223> Chimeric AAV capsid nucleotide sequence

<400> 1

25 atggctgccg atggttatct tccagattgg ctcgaggaca ctctctctga aggaataaga 60
 cagtgggtgga agctcaaacc tggcccacca ccaccaaagc ccgcagagcg gcataaggac 120
 gacagcaggg gtcttgtgct tcctgggtac aagtacctcg gacccttcaa cggactcgac 180
 30 aagggagagc cgggtcaacga ggagacgccc gcggccctcg agcacgacaa agcctacgac 240
 cggcagctcg acagcggaga caaccctgac ctcaagtaca accacgccga cgcgaggttt 300
 caggagcgcc ttaaagaaga tacgtctttt gggggcaacc tcgggagagc agtcttccag 360
 35 gccaaaaaga ggcttcttga acctcttggt ctggttgagg aagcggctaa gacggctcct 420
 ggaaagaaga ggcctgtaga gcagtctcct caggaaccgg actcctcctc gggcatcggc 480
 aagacaggcc agcagcccgc taaaaagaga ctcaatttcg gtcagactgg cgacacagag 540
 40 tcagtcccag accctcaacc aatcggagaa cctcccgag cccctcagg tgtgggatct 600
 cttacaatgg cttcaggtgg tggcgacca gtggcagaca ataacgaagg tgccgatgga 660
 gtgggtagtt cctcgggaaa ttggcattgc gattcccaat ggctggggga cagagtcatc 720
 45 accaccagca cccgaacctg ggcctgccc acctacaaca atcacctcta caagcaaatac 780
 tccaacggga catcgggagg agccaccaac gacaacacct acttcggcta cagcaccctc 840
 tgggggtatt ttgactttaa cagattccac tgccactttt caccacgtga ctggcagcga 900
 50 ctcatcaaca acaactgggg attccggccc aagagactca gcttcaagct cttcaacatc 960
 caggtcaagg aggtcacgca gaatgaaggc accaagacca tcgccaataa ccttaccagc 1020
 55 acggtccagg tcttcacgga ctcgagtagc cagctgccgt acgttctcgg ctctgcccac 1080
 cagggctgcc tgccctcggt cccggcgagc gtgttcatga ttcccagta cggctaccta 1140

EP 3 738 974 A1

	acactcaaca acggtagtca ggccgtggga cgctcctcct tctactgcct ggaatacttt	1200
	ccttcgcaga tgctgagaac cggcaacaac ttccagttta cttacacctt cgaggacgtg	1260
5	cctttccaca gcagctacgc ccacagccag agcttggacc ggctgatgaa tcctctgatt	1320
	gaccagtacc tgtactactt gtctcggact caaacaacag gaggcacggc aaatacgcag	1380
	actctgggct tcagccaagg tgggcctaata acaatggcca atcaggcaaa gaactggctg	1440
10	ccaggaccct gttaccgcca acaacgcgtc tcaacgacaa ccgggcaaaa caacaatagc	1500
	aactttgcct ggactgctgg gaccaaatac catctgaatg gaagaaattc attggctaata	1560
	cctggcatcg ctatggcaac acacaaagac gacaaggagc gtttttttcc cagtaacggg	1620
15	atcctgattt ttggcaaaca aaatgctgcc agagacaatg cggattacag cgatgtcatg	1680
	ctcaccagcg aggaagaaat caaaaccact aaccctgtgg ctacagagga atacggtatc	1740
20	gtggcagata acttgcagca gcaaaacacg gctcctcaaa ttggaactgt caacagccag	1800
	ggggccttac ccggtatggt ttggcagaac cgggacgtgt acctgcaggg tcccatctgg	1860
	gccaagattc ctcacacgga cggcaacttc caccctgtc cgctgatggg cggctttggc	1920
25	ctgaaacatc ctccgcctca gatcctgatc aagaacacgc ctgtacctgc ggatcctccg	1980
	accaccttca accagtcaaa gctgaactct ttcattcacgc aatacagcac cggacaggtc	2040
	agcgtggaaa ttgaatggga gctgcagaag gaaaacagca agcgtggaa ccccgagatc	2100
30	cagtacacct ccaactacta caaatctaca agtgtggact ttgctgttaa tacagaaggc	2160
	gtgtactctg aacccccacc cattggcacc cgttacctca cccgtcccct gtaa	2214
35	<210> 2 <211> 737 <212> PRT <213> Artificial	
40	<220> <223> Chimeric AAC capsid amino acid sequence <400> 2	
45	Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Thr Leu Ser	
	1 5 10 15	
	Glu Gly Ile Arg Gln Trp Trp Lys Leu Lys Pro Gly Pro Pro Pro Pro	
50	20 25 30	
	Lys Pro Ala Glu Arg His Lys Asp Asp Ser Arg Gly Leu Val Leu Pro	
	35 40 45	
55	Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro	
	50 55 60	

EP 3 738 974 A1

	Val	Asn	Glu	Ala	Asp	Ala	Ala	Ala	Leu	Glu	His	Asp	Lys	Ala	Tyr	Asp	65	70	75	80
5	Arg	Gln	Leu	Asp	Ser	Gly	Asp	Asn	Pro	Tyr	Leu	Lys	Tyr	Asn	His	Ala	85	90	95	
10	Asp	Ala	Glu	Phe	Gln	Glu	Arg	Leu	Lys	Glu	Asp	Thr	Ser	Phe	Gly	Gly	100	105	110	
	Asn	Leu	Gly	Arg	Ala	Val	Phe	Gln	Ala	Lys	Lys	Arg	Leu	Leu	Glu	Pro	115	120	125	
15	Leu	Gly	Leu	Val	Glu	Glu	Ala	Ala	Lys	Thr	Ala	Pro	Gly	Lys	Lys	Arg	130	135	140	
20	Pro	Val	Glu	Gln	Ser	Pro	Gln	Glu	Pro	Asp	Ser	Ser	Ser	Gly	Ile	Gly	145	150	155	160
	Lys	Thr	Gly	Gln	Gln	Pro	Ala	Lys	Lys	Arg	Leu	Asn	Phe	Gly	Gln	Thr	165	170	175	
25	Gly	Asp	Thr	Glu	Ser	Val	Pro	Asp	Pro	Gln	Pro	Ile	Gly	Glu	Pro	Pro	180	185	190	
30	Ala	Ala	Pro	Ser	Gly	Val	Gly	Ser	Leu	Thr	Met	Ala	Ser	Gly	Gly	Gly	195	200	205	
35	Ala	Pro	Val	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Ser	Ser	210	215	220	
	Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Gln	Trp	Leu	Gly	Asp	Arg	Val	Ile	225	230	235	240
40	Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	Pro	Thr	Tyr	Asn	Asn	His	Leu	245	250	255	
45	Tyr	Lys	Gln	Ile	Ser	Asn	Gly	Thr	Ser	Gly	Gly	Ala	Thr	Asn	Asp	Asn	260	265	270	
	Thr	Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	275	280	285	
50	Phe	His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	290	295	300	
55	Asn	Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Ser	Phe	Lys	Leu	Phe	Asn	Ile	305	310	315	320

EP 3 738 974 A1

	Gln	Val	Lys	Glu	Val	Thr	Gln	Asn	Glu	Gly	Thr	Lys	Thr	Ile	Ala	Asn	
					325					330					335		
5	Asn	Leu	Thr	Ser	Thr	Val	Gln	Val	Phe	Thr	Asp	Ser	Glu	Tyr	Gln	Leu	
				340					345					350			
10	Pro	Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	
			355					360					365				
15	Ala	Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	
		370					375					380					
20	Gly	Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	
	385					390					395					400	
25	Pro	Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Gln	Phe	Thr	Tyr	Thr	
				405						410					415		
30	Phe	Glu	Asp	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	
			420						425					430			
35	Asp	Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Ser	
			435					440					445				
40	Arg	Thr	Gln	Thr	Thr	Gly	Gly	Thr	Ala	Asn	Thr	Gln	Thr	Leu	Gly	Phe	
	450					455						460					
45	Ser	Gln	Gly	Gly	Pro	Asn	Thr	Met	Ala	Asn	Gln	Ala	Lys	Asn	Trp	Leu	
	465					470					475					480	
50	Pro	Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Thr	Thr	Thr	Gly	Gln	
				485					490						495		
55	Asn	Asn	Asn	Ser	Asn	Phe	Ala	Trp	Thr	Ala	Gly	Thr	Lys	Tyr	His	Leu	
			500						505					510			
60	Asn	Gly	Arg	Asn	Ser	Leu	Ala	Asn	Pro	Gly	Ile	Ala	Met	Ala	Thr	His	
		515						520					525				
65	Lys	Asp	Asp	Lys	Glu	Arg	Phe	Phe	Pro	Ser	Asn	Gly	Ile	Leu	Ile	Phe	
	530						535					540					
70	Gly	Lys	Gln	Asn	Ala	Ala	Arg	Asp	Asn	Ala	Asp	Tyr	Ser	Asp	Val	Met	
	545					550					555					560	
75	Leu	Thr	Ser	Glu	Glu	Glu	Ile	Lys	Thr	Thr	Asn	Pro	Val	Ala	Thr	Glu	

EP 3 738 974 A1

565

570

575

5

Glu Tyr Gly Ile Val Ala Asp Asn Leu Gln Gln Gln Asn Thr Ala Pro
580 585 590

10

Gln Ile Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp
595 600 605

15

Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro
610 615 620

His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly
625 630 635 640

20

Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro
645 650 655

Ala Asp Pro Pro Thr Thr Phe Asn Gln Ser Lys Leu Asn Ser Phe Ile
660 665 670

25

Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu
675 680 685

30

Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser
690 695 700

Asn Tyr Tyr Lys Ser Thr Ser Val Asp Phe Ala Val Asn Thr Glu Gly
705 710 715 720

35

Val Tyr Ser Glu Pro His Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro
725 730 735

40

Leu

45

<210> 3
<211> 736
<212> PRT
<213> Artificial

<220>
<223> Chimeric AAC capsid amino acid sequence

50

<400> 3

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15

55

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
20 25 30

EP 3 738 974 A1

	Lys	Ala	Asn	Gln	Gln	Lys	Gln	Asp	Asp	Gly	Arg	Gly	Leu	Val	Leu	Pro	
			35					40					45				
5	Gly	Tyr	Lys	Tyr	Leu	Gly	Pro	Phe	Asn	Gly	Leu	Asp	Lys	Gly	Glu	Pro	
		50					55					60					
10	Val	Asn	Ala	Ala	Asp	Ala	Ala	Ala	Leu	Glu	His	Asp	Lys	Ala	Tyr	Asp	
	65					70					75					80	
15	Gln	Gln	Leu	Lys	Ala	Gly	Asp	Asn	Pro	Tyr	Leu	Arg	Tyr	Asn	His	Ala	
					85					90					95		
20	Asp	Ala	Glu	Phe	Gln	Glu	Arg	Leu	Gln	Glu	Asp	Thr	Ser	Phe	Gly	Gly	
				100					105						110		
25	Asn	Leu	Gly	Arg	Ala	Val	Phe	Gln	Ala	Lys	Lys	Arg	Val	Leu	Glu	Pro	
			115					120					125				
30	Leu	Gly	Leu	Val	Glu	Glu	Gly	Ala	Lys	Thr	Ala	Pro	Gly	Lys	Lys	Arg	
		130					135					140					
35	Pro	Val	Glu	Gln	Ser	Pro	Gln	Glu	Pro	Asp	Ser	Ser	Ser	Gly	Ile	Gly	
	145					150					155					160	
40	Lys	Thr	Gly	Gln	Gln	Pro	Ala	Lys	Lys	Arg	Leu	Asn	Phe	Gly	Gln	Thr	
					165					170					175		
45	Gly	Asp	Thr	Glu	Ser	Val	Pro	Asp	Pro	Gln	Pro	Ile	Gly	Glu	Pro	Pro	
				180					185					190			
50	Ala	Ala	Pro	Ser	Gly	Val	Gly	Ser	Leu	Thr	Met	Ala	Ser	Gly	Gly	Gly	
			195					200					205				
55	Ala	Pro	Val	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Ser	Ser	
		210					215					220					
60	Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Gln	Trp	Leu	Gly	Asp	Arg	Val	Ile	
	225					230					235					240	
65	Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	Pro	Thr	Tyr	Asn	Asn	His	Leu	
					245					250					255		
70	Tyr	Lys	Gln	Ile	Ser	Ser	Ala	Ser	Thr	Gly	Ala	Ser	Asn	Asp	Asn	His	
				260					265					270			
75	Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	Phe	

EP 3 738 974 A1

	275					280					285					
5	His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	Asn
		290					295					300				
10	Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	Leu	Phe	Asn	Ile	Gln
	305					310					315					320
15	Val	Lys	Glu	Val	Thr	Asp	Asn	Asn	Gly	Val	Lys	Thr	Ile	Ala	Asn	Asn
					325					330					335	
20	Leu	Thr	Ser	Thr	Val	Gln	Val	Phe	Thr	Asp	Ser	Asp	Tyr	Gln	Leu	Pro
				340					345					350		
25	Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	Ala
			355					360					365			
30	Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	Gly
	370						375					380				
35	Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	Pro
	385					390					395					400
40	Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Gln	Phe	Thr	Tyr	Thr	Phe
				405						410					415	
45	Glu	Asp	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	Asp
				420					425					430		
50	Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Ser	Arg
			435					440					445			
55	Thr	Gln	Thr	Thr	Gly	Gly	Thr	Ala	Asn	Thr	Gln	Thr	Leu	Gly	Phe	Ser
		450					455					460				
60	Gln	Gly	Gly	Pro	Asn	Thr	Met	Ala	Asn	Gln	Ala	Lys	Asn	Trp	Leu	Pro
	465					470					475					480
65	Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Thr	Thr	Thr	Gly	Gln	Asn
					485					490					495	
70	Asn	Asn	Ser	Asn	Phe	Ala	Trp	Thr	Ala	Gly	Thr	Lys	Tyr	His	Leu	Asn
				500					505					510		
75	Gly	Arg	Asn	Ser	Leu	Ala	Asn	Pro	Gly	Ile	Ala	Met	Ala	Thr	His	Lys
			515					520					525			

EP 3 738 974 A1

	Asp	Asp	Lys	Glu	Arg	Phe	Phe	Pro	Ser	Asn	Gly	Ile	Leu	Ile	Phe	Gly
	530						535					540				
5	Lys	Gln	Asn	Ala	Ala	Arg	Asp	Asn	Ala	Asp	Tyr	Ser	Asp	Val	Met	Leu
	545					550					555					560
	Thr	Ser	Glu	Glu	Glu	Ile	Lys	Thr	Thr	Asn	Pro	Val	Ala	Thr	Glu	Glu
10					565					570					575	
	Tyr	Gly	Ile	Val	Ala	Asp	Asn	Leu	Gln	Gln	Gln	Asn	Thr	Ala	Pro	Gln
				580					585					590		
15	Ile	Gly	Thr	Val	Asn	Ser	Gln	Gly	Ala	Leu	Pro	Gly	Met	Val	Trp	Gln
			595					600					605			
	Asn	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	His
20		610					615					620				
	Thr	Asp	Gly	Asn	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly	Leu
	625					630					635					640
25	Lys	His	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	Pro	Ala
					645					650					655	
	Asp	Pro	Pro	Thr	Thr	Phe	Asn	Gln	Ser	Lys	Leu	Asn	Ser	Phe	Ile	Thr
30				660					665					670		
	Gln	Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	Leu	Gln
35			675					680					685			
	Lys	Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Ile	Gln	Tyr	Thr	Ser	Asn
		690					695					700				
40	Tyr	Tyr	Lys	Ser	Thr	Ser	Val	Asp	Phe	Ala	Val	Asn	Thr	Glu	Gly	Val
	705					710					715					720
	Tyr	Ser	Glu	Pro	His	Pro	Ile	Gly	Thr	Arg	Tyr	Leu	Thr	Arg	Pro	Leu
45					725					730					735	
	<210>	4														
	<211>	736														
	<212>	PRT														
50	<213>	Artificial														
	<220>															
	<223>	Chimeric AAC capsid amino acid sequence														
55	<400>	4														
	Met	Ala	Ala	Asp	Gly	Tyr	Leu	Pro	Asp	Trp	Leu	Glu	Asp	Thr	Leu	Ser

EP 3 738 974 A1

	1		5				10				15					
5	Glu	Gly	Ile	Arg	Gln	Trp	Trp	Lys	Leu	Lys	Pro	Gly	Pro	Pro	Pro	Pro
				20					25				30			
	Lys	Pro	Ala	Glu	Arg	His	Lys	Asp	Asp	Ser	Arg	Gly	Leu	Val	Leu	Pro
			35					40					45			
10	Gly	Tyr	Lys	Tyr	Leu	Gly	Pro	Phe	Asn	Gly	Leu	Asp	Lys	Gly	Glu	Pro
		50					55					60				
15	Val	Asn	Glu	Ala	Asp	Ala	Ala	Ala	Leu	Glu	His	Asp	Lys	Ala	Tyr	Asp
	65					70					75					80
	Arg	Gln	Leu	Asp	Ser	Gly	Asp	Asn	Pro	Tyr	Leu	Lys	Tyr	Asn	His	Ala
20					85					90					95	
	Asp	Ala	Glu	Phe	Gln	Glu	Arg	Leu	Gln	Gly	Asp	Thr	Ser	Phe	Gly	Gly
				100					105					110		
25	Asn	Leu	Gly	Arg	Ala	Val	Phe	Gln	Ala	Lys	Lys	Arg	Val	Leu	Glu	Pro
			115					120					125			
	Leu	Gly	Leu	Val	Glu	Glu	Gly	Ala	Lys	Thr	Ala	Pro	Gly	Lys	Lys	Arg
30			130				135					140				
	Pro	Val	Glu	Gln	Ser	Pro	Gln	Glu	Pro	Asp	Ser	Ser	Ser	Gly	Ile	Gly
35						150					155					160
	Glu	Thr	Gly	Gln	Gln	Pro	Ala	Lys	Lys	Arg	Leu	Asn	Phe	Gly	Gln	Thr
				165						170					175	
40	Gly	Asp	Ser	Glu	Ser	Val	Pro	Asp	Pro	Gln	Pro	Leu	Gly	Glu	Pro	Pro
				180					185					190		
	Ala	Thr	Pro	Ala	Ala	Val	Gly	Pro	Thr	Thr	Met	Ala	Ser	Gly	Gly	Gly
45			195					200					205			
	Ala	Pro	Met	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Ser	Ser
		210					215					220				
50	Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Gln	Trp	Leu	Gly	Asp	Arg	Val	Ile
	225					230					235					240
	Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	Pro	Thr	Tyr	Asn	Asn	His	Leu
55					245					250					255	

EP 3 738 974 A1

	Tyr	Lys	Gln	Ile	Ser	Ser	Ala	Ser	Thr	Gly	Ala	Ser	Asn	Asp	Asn	His	
				260					265					270			
5	Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	Phe	
			275					280					285				
10	His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	Asn	
		290					295					300					
15	Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Ser	Phe	Lys	Leu	Phe	Asn	Ile	Gln	
	305					310					315					320	
20	Val	Lys	Glu	Val	Thr	Asp	Asn	Asn	Gly	Val	Lys	Thr	Ile	Ala	Asn	Asn	
					325					330					335		
25	Leu	Thr	Ser	Thr	Val	Gln	Val	Phe	Thr	Asp	Ser	Glu	Tyr	Gln	Leu	Pro	
				340					345					350			
30	Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	Ala	
			355					360					365				
35	Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	Gly	
		370					375					380					
40	Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	Pro	
						390					395					400	
45	Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Thr	Phe	Ser	Tyr	Thr	Phe	
				405						410					415		
50	Glu	Asp	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	Asp	
			420						425					430			
55	Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Ser	Arg	
			435					440					445				
60	Thr	Gln	Thr	Thr	Gly	Gly	Thr	Ala	Asn	Thr	Gln	Thr	Leu	Gly	Phe	Ser	
		450				455						460					
65	Gln	Gly	Gly	Pro	Asn	Thr	Met	Ala	Asn	Gln	Ala	Lys	Asn	Trp	Leu	Pro	
	465					470					475					480	
70	Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Thr	Thr	Thr	Gly	Gln	Asn	
					485					490					495		
75	Asn	Asn	Ser	Asn	Phe	Ala	Trp	Thr	Ala	Gly	Thr	Lys	Tyr	His	Leu	Asn	
				500					505					510			

EP 3 738 974 A1

	Gly	Arg	Asn	Ser	Leu	Ala	Asn	Pro	Gly	Ile	Ala	Met	Ala	Thr	His	Lys
			515					520					525			
5	Asp	Asp	Lys	Glu	Arg	Phe	Phe	Pro	Ser	Asn	Gly	Ile	Leu	Ile	Phe	Gly
		530					535					540				
10	Lys	Gln	Asn	Ala	Ala	Arg	Asp	Asn	Ala	Asp	Tyr	Ser	Asp	Val	Met	Leu
	545					550					555					560
15	Thr	Ser	Glu	Glu	Glu	Ile	Lys	Thr	Thr	Asn	Pro	Val	Ala	Thr	Glu	Glu
					565					570					575	
20	Tyr	Gly	Ile	Val	Ala	Asp	Asn	Leu	Gln	Gln	Gln	Asn	Thr	Ala	Pro	Gln
				580					585					590		
25	Ile	Gly	Thr	Val	Asn	Ser	Gln	Gly	Ala	Leu	Pro	Gly	Met	Val	Trp	Gln
			595					600					605			
30	Asn	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	His
		610					615					620				
35	Thr	Asp	Gly	Asn	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly	Leu
	625					630					635					640
40	Lys	His	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	Pro	Ala
					645					650					655	
45	Asp	Pro	Pro	Thr	Thr	Phe	Asn	Gln	Ser	Lys	Leu	Asn	Ser	Phe	Ile	Thr
				660					665					670		
50	Gln	Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	Leu	Gln
			675					680					685			
55	Lys	Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Ile	Gln	Tyr	Thr	Ser	Asn
	690						695					700				
60	Tyr	Tyr	Lys	Ser	Thr	Ser	Val	Asp	Phe	Ala	Val	Asn	Thr	Glu	Gly	Val
	705					710					715					720
65	Tyr	Ser	Glu	Pro	His	Pro	Ile	Gly	Thr	Arg	Tyr	Leu	Thr	Arg	Pro	Leu
					725					730					735	

Claims

1. A nucleic acid encoding an AAV capsid, the nucleic acid comprising an AAV capsid coding sequence that is at least 90% identical to:

- (a) the nucleotide sequence of SEQ ID NO: 1; or
- (b) a nucleotide sequence encoding one of SEQ ID NOS:2-4.

2. The nucleic acid of claim 1, wherein the nucleic acid is a plasmid, phage, viral vector, bacterial artificial chromosome, or yeast artificial chromosome.
3. A virus particle comprising the nucleic acid of any one of claims 1-2.
4. An AAV capsid comprising an amino acid sequence at least 96% identical to one of SEQ ID NOS:2-4.
5. The AAV capsid of claim 4 covalently linked, bound to, or encapsidating a compound selected from the group consisting of a DNA molecule, an RNA molecule, a polypeptide, a carbohydrate, a lipid, and a small organic molecule.
6. An AAV particle comprising:
 - an AAV vector genome; and
 - the AAV capsid of any one of claims 4-5, wherein the AAV capsid encapsidates the AAV vector genome.
7. The AAV particle of claim 6, wherein the heterologous nucleic acid encodes a therapeutic polypeptide.
8. The AAV particle of claim 6, wherein the heterologous nucleic acid encodes a growth factor or differentiation factor.
9. The AAV particle of claim 6, wherein the heterologous nucleic acid encodes insulin growth factor-1, glial-derived neurotrophic factor, neurotrophin-3, artemin, transforming growth factor alpha, platelet-derived growth factor, leukemia inhibitory factor, prolactin, monocarboxylate transporter 1, or nuclear factor 1A.
10. A method of producing a recombinant AAV particle comprising an AAV capsid, the method comprising:
 - providing a cell *in vitro* with a nucleic acid according to any one of claims 1-2, an AAV rep coding sequence, an AAV vector genome comprising a heterologous nucleic acid, and helper functions for generating a productive AAV infection; and
 - allowing assembly of the recombinant AAV particle comprising the AAV capsid and encapsidating the AAV vector genome.
11. An AAV particle produced by the method of claim 10.
12. A pharmaceutical formulation comprising the nucleic acid of any one of claims 1-2, the virus particle of claim 3, the AAV capsid of any one of claims 4-5, or the AAV particle of any one of claims 6-8 or 11 in a pharmaceutically acceptable carrier.
13. A method of delivering a nucleic acid of interest to an oligodendrocyte, the method comprising contacting the oligodendrocyte with the AAV particle of any one of claims 6-8 or 11.
14. A method of preparing an AAV capsid having a tropism profile of interest, the method comprising modifying the AAV capsid of any one of claims 4-5 to insert an amino acid sequence providing the tropism profile of interest.
15. The method of claim 14, wherein the tropism profile of interest is a tissue selected from skeletal muscle, liver, cardiac muscle, diaphragm, kidney, liver, pancreas, spleen, gastrointestinal tract, lung, joint tissue, tongue, ovary, testis, a germ cell, a cancer cell, or a combination thereof.




FIG. 1




FIG. 2




FIG. 3





FIG. 4

CONFOCAL IMAGE OF GFP-NEUN CO-LOCALIZATION IN THE STRIATUM



NOTE THE LACK OF NEUN CO-LOCALIZATION WITH THE MANY OLIGODENDROCYTES THAT SURROUND THE LONE NEUN POSITIVE NEURON

FIG. 5




FIG. 6



EUROPEAN SEARCH REPORT

 Application Number
EP 20 17 8708

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	WO 2006/110689 A2 (UNIV PENNSYLVANIA [US]; VANDENBERGHE LUK [US]; GAO GUANGPING [US]; WIL) 19 October 2006 (2006-10-19) * sequences 15,21 *	1-3, 10-12	INV. C07K14/015 C12N15/86 C12N15/35 C12N15/63 C12N15/19 C12N15/09 C12N7/00 C12N5/10 A61K48/00 A61K35/76 A61P25/00
X	WO 2004/108922 A2 (UNIV PENNSYLVANIA [US]; RADER DANIEL J [US]; WILSON JAMES M [US]) 16 December 2004 (2004-12-16) * examples 1,2; sequence 8 *	1-3, 10-12	
X	EP 2 345 731 A1 (UNIV PENNSYLVANIA [US]) 20 July 2011 (2011-07-20) * sequences 43, 182, 214 *	1-3, 10-12	
X	US 2003/228282 A1 (GAO GUANGPING [US] ET AL) 11 December 2003 (2003-12-11) * paragraph [0137]; claim 8; table 1; sequence 1 *	1-3, 10-12	
A	US 2012/009268 A1 (ASOKAN ARAVIND [US] ET AL) 12 January 2012 (2012-01-12) * the whole document *	14,15	TECHNICAL FIELDS SEARCHED (IPC)
A	HONG CHEN ET AL: "Oligodendrocyte-specific gene expression in mouse brain: Use of a myelin-forming cell type-specific promoter in an adeno-associated virus", JOURNAL OF NEUROSCIENCE RESEARCH., vol. 55, no. 4, 15 February 1999 (1999-02-15), pages 504-513, XP055240063, US ISSN: 0360-4012, DOI: 10.1002/(SICI)1097-4547(19990215)55:4<504: :AID-JNR10>3.0.CO;2-0 * the whole document *	13	C07K C12N A61K
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 5 October 2020	Examiner Brenz Verca, Stefano
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 20 17 8708

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A,D	US 5 478 745 A (SAMULSKI RICHARD J [US] ET AL) 26 December 1995 (1995-12-26) -----	1-15	
A	US 2012/202745 A1 (O'SHEA KATHY SUE [US] ET AL) 9 August 2012 (2012-08-09) -----	1-15	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (IPC)
Place of search		Date of completion of the search	Examiner
Munich		5 October 2020	Brenz Verca, Stefano
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 20 17 8708

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

05-10-2020

10

Patent document
cited in search report

Publication
date

Patent family
member(s)

Publication
date

15

WO 2006110689 A2 19-10-2006

CN 101203613 A 18-06-2008

CN 102994549 A 27-03-2013

CN 104293835 A 21-01-2015

CN 106906241 A 30-06-2017

DK 2359867 T3 05-01-2015

DK 2383346 T3 05-01-2015

EP 1866422 A2 19-12-2007

EP 2357010 A1 17-08-2011

EP 2359865 A1 24-08-2011

EP 2359866 A1 24-08-2011

EP 2359867 A1 24-08-2011

EP 2383346 A1 02-11-2011

EP 3085389 A1 26-10-2016

EP 3409296 A1 05-12-2018

EP 3603676 A1 05-02-2020

ES 2426245 T3 22-10-2013

ES 2428218 T3 06-11-2013

ES 2434723 T3 17-12-2013

ES 2525067 T3 17-12-2014

ES 2525143 T3 18-12-2014

ES 2580044 T3 18-08-2016

JP 5677681 B2 25-02-2015

JP 5702519 B2 15-04-2015

JP 5912147 B2 27-04-2016

JP 6039632 B2 07-12-2016

JP 6275769 B2 07-02-2018

JP 2008538286 A 23-10-2008

JP 2012165744 A 06-09-2012

JP 2014204723 A 30-10-2014

JP 2015096070 A 21-05-2015

JP 2016168047 A 23-09-2016

US 2009197338 A1 06-08-2009

US 2015159173 A1 11-06-2015

US 2017191079 A1 06-07-2017

US 2018057841 A1 01-03-2018

US 2019218574 A1 18-07-2019

US 2020208176 A1 02-07-2020

WO 2006110689 A2 19-10-2006

WO 2004108922 A2 16-12-2004 NONE

EP 2345731 A1 20-07-2011

AU 2004278684 A1 14-04-2005

AU 2008203421 A1 21-08-2008

CA 2537793 A1 14-04-2005

CA 2939103 A1 14-04-2005

CA 3072423 A1 14-04-2005

50

ORM P0459

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 20 17 8708

5

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

05-10-2020

10

15

20

25

30

35

40

45

50

55

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		CN 1856576 A	01-11-2006
		CN 102174574 A	07-09-2011
		CN 102199626 A	28-09-2011
		CN 102212558 A	12-10-2011
		CN 102220376 A	19-10-2011
		CY 1119833 T1	27-06-2018
		DK 2292779 T3	27-02-2017
		DK 2292780 T3	04-12-2017
		DK 2345731 T3	25-01-2016
		EP 1668143 A2	14-06-2006
		EP 2292779 A2	09-03-2011
		EP 2292780 A2	09-03-2011
		EP 2298926 A1	23-03-2011
		EP 2345731 A1	20-07-2011
		EP 3211085 A1	30-08-2017
		ES 2411479 T3	05-07-2013
		ES 2555612 T3	05-01-2016
		ES 2616016 T3	09-06-2017
		ES 2648241 T3	29-12-2017
		HU E033158 T2	28-11-2017
		HU E035567 T2	28-05-2018
		JP 5054975 B2	24-10-2012
		JP 5431516 B2	05-03-2014
		JP 5797397 B2	21-10-2015
		JP 5911069 B2	27-04-2016
		JP 6335141 B2	30-05-2018
		JP 6516713 B2	22-05-2019
		JP 6673963 B2	01-04-2020
		JP 2007507223 A	29-03-2007
		JP 2011101646 A	26-05-2011
		JP 2012175974 A	13-09-2012
		JP 2014012022 A	23-01-2014
		JP 2015163083 A	10-09-2015
		JP 2017060483 A	30-03-2017
		JP 2018108113 A	12-07-2018
		JP 2020054373 A	09-04-2020
		NZ 545628 A	30-04-2009
		PL 2292780 T3	30-05-2018
		PT 2292780 T	28-11-2017
		SI 2292780 T1	29-12-2017
		US 2007036760 A1	15-02-2007
		US 2011236353 A1	29-09-2011
		US 2015315612 A1	05-11-2015
		US 2017028082 A1	02-02-2017
		US 2017159027 A1	08-06-2017
		US 2019015527 A1	17-01-2019

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 20 17 8708

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

05-10-2020

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		US 2019022249 A1	24-01-2019
		US 2019054188 A1	21-02-2019
		US 2020155704 A1	21-05-2020
		WO 2005033321 A2	14-04-2005
US 2003228282 A1	11-12-2003	AU 2002360291 A1	30-06-2003
		CA 2469785 A1	26-06-2003
		CY 1120162 T1	12-12-2018
		CY 1121446 T1	29-05-2020
		DK 1453547 T3	05-12-2016
		DK 2359869 T3	15-04-2019
		EP 1453547 A2	08-09-2004
		EP 2359869 A2	24-08-2011
		EP 3517134 A1	31-07-2019
		ES 2602352 T3	20-02-2017
		ES 2717377 T3	20-06-2019
		JP 4810062 B2	09-11-2011
		JP 5649529 B2	07-01-2015
		JP 2005512533 A	12-05-2005
		JP 2011254821 A	22-12-2011
		PT 1453547 T	28-12-2016
		PT 2359869 T	16-04-2019
		US 2003228282 A1	11-12-2003
		US 2008075737 A1	27-03-2008
		US 2008075740 A1	27-03-2008
		US 2009227030 A1	10-09-2009
		US 2014004143 A1	02-01-2014
		US 2015139953 A1	21-05-2015
		US 2015176027 A1	25-06-2015
		US 2016201088 A1	14-07-2016
		US 2017088858 A1	30-03-2017
		US 2017306354 A1	26-10-2017
		US 2019017068 A1	17-01-2019
		US 2019292563 A1	26-09-2019
		US 2020283799 A1	10-09-2020
		WO 03052051 A2	26-06-2003
US 2012009268 A1	12-01-2012	EP 2396343 A2	21-12-2011
		ES 2634118 T3	26-09-2017
		US 2012009268 A1	12-01-2012
		US 2015152142 A1	04-06-2015
		WO 2010093784 A2	19-08-2010
US 5478745 A	26-12-1995	AT 423203 T	15-03-2009
		EP 0673415 A1	27-09-1995
		JP 4117023 B2	09-07-2008

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 20 17 8708

5

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

05-10-2020

10

15

20

25

30

35

40

45

50

55

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		JP H08504102 A	07-05-1996
		KR 100256890 B1	15-05-2000
		TW 260708 B	21-10-1995
		US 5478745 A	26-12-1995
		WO 9413788 A1	23-06-1994

US 2012202745 A1	09-08-2012	US 2012202745 A1	09-08-2012
		WO 2010147803 A2	23-12-2010

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 0028061 A [0028]
- WO 9961601 A [0028]
- WO 9811244 A [0028]
- US 6156303 A [0028]
- US 5478745 A, Samulski [0048]
- WO 0028004 A [0058]
- WO 0192551 A [0059]
- US 7465583 B [0059]
- US 2003017131 A [0064]
- US 20070026076 A [0064]
- US 5877022 A [0066]
- US 6013487 A [0066]
- US 6083702 A [0066]
- US 5869248 A, Yuan [0066]
- US 6653467 B [0067]
- US 6727355 B [0067]
- US 6653466 B [0067]
- US 5354855 A [0069]
- US 5023243 A, Tullis [0071]
- US 5149797 A, Pederson [0071]
- WO 0177350 A [0081]
- US 5916563 A, Young [0092]
- WO 5905040 A, Mazzara [0092]
- US 5882652 A [0092]
- US 5863541 A, Samulski [0092] [0102]
- US 4968603 A [0094]
- WO 9005142 A [0094]
- US 6040183 A [0123]
- US 6093570 A [0123]
- WO 0017377 A [0131]
- US 5658785 A [0133]
- US 4474893 A [0137]
- US 4816567 A [0137]
- US 4676980 A [0137]
- WO 2003095647 A [0151]
- WO 2006021724 A [0151]
- US 20060287259 A [0154]
- US 20070059288 A [0154]
- US 5399346 A [0184]
- WO 0191803 A [0194]
- US 7201898 B [0201] [0207]
- US 4501729 A [0216]
- WO 2012093784 A [0218]
- WO 2009137006 A [0219]

Non-patent literature cited in the description

- XIAO et al. *J. Virol.*, 1996, vol. 70, 8098-8108 [0001]
- SCHNEPP et al. *J. Virol.*, 2003, vol. 77, 3495-3504 [0001]
- MANNO et al. *Blood*, 2003, vol. 101, 2963-2972 [0001]
- GRAY et al. *Mol. Ther.*, 2010, vol. 18, 570-578 [0002]
- SAMBROOK et al. MOLECULAR CLONING: A LABORATORY MANUAL. Cold Spring Harbor, 1989 [0020]
- F. M. AUSUBEL et al. CURRENT PROTOCOLS IN MOLECULAR BIOLOGY. John Wiley & Sons, Inc, [0020]
- BERNARD N. FIELDS et al. VIROLOGY. Lippincott-Raven Publishers, vol. 2 [0027]
- GAO et al. *J. Virol.*, 2004, vol. 78, 6381-6388 [0027]
- SRIVISTAVA et al. *J. Virol.*, 1983, vol. 45, 555 [0028]
- CHIORINI et al. *J. Virol.*, 1998, vol. 71, 6823 [0028]
- CHIORINI et al. *J. Virol.*, 1999, vol. 73, 1309 [0028]
- BANTELS-SCHAAL et al. *J. Virol.*, 1999, vol. 73, 939 [0028]
- XIAO et al. *J. Virol.*, 1999, vol. 73, 3994 [0028]
- MURAMATSU et al. *Virology*, 1996, vol. 221, 208 [0028]
- SHADE et al. *J. Virol.*, 1986, vol. 58, 921 [0028]
- GAO et al. *Proc. Nat. Acad. Sci. USA*, 2002, vol. 99, 11854 [0028]
- Characterization of Adeno- associated virus (AAV) DNA replication and integration. XIAO, X. Ph.D. Dissertation, University of Pittsburgh. 1996 [0028]
- FIELDS et al. VIROLOGY. Lippincott-Raven Publishers, vol. 2 [0051]
- NICKLIN et al. *Mol. Ther.*, 2001, 474-181 [0058]
- WHITE et al. *Circulation*, 2004, vol. 109, 513-319 [0058]
- MULLER et al. *Nature Biotech.*, 2003, vol. 21, 1040-1046 [0058]
- VINCENT et al. *Nature Genetics*, vol. 5, 130 [0064]
- WANG et al. *Proc. Natl. Acad. Sci. USA*, 2000, vol. 97, 13714-9 [0064]
- HARPER et al. *Nature Med.*, 2002, vol. 8, 253-61 [0064]
- PUTTARAJU et al. *Nature Biotech.*, 1999, vol. 17, 246 [0066]
- SHARP et al. *Science*, 2000, vol. 287, 2431 [0066]
- GORMAN et al. *Proc. Nat. Acad. Sci. USA*, 1998, vol. 95, 4929 [0066]

- **GOYENVALLE et al.** *Science*, 2004, vol. 306, 1796-1799 [0067]
- **DENTI et al.** *Proc. Nat. Acad. Sci. USA*, 2006, vol. 103, 3758-3763 [0067]
- **KIM et al.** *Proc. Natl. Acad. Sci. USA*, 1987, vol. 84, 8788 [0068]
- **GERLACH et al.** *Nature*, 1987, vol. 328, 802 [0068]
- **FORSTER ; SYMONS.** *Cell*, 1987, vol. 49, 211 [0068]
- **MICHEL ; WESTHOF.** *J. Mol. Biol.*, 1990, vol. 216, 585 [0068]
- **REINHOLD-HUREK ; SHUB.** *Nature*, 1992, vol. 357, 173 [0068]
- **JOYCE.** *Nature*, 1989, vol. 338, 217 [0069]
- **SCANLON et al.** *Proc. Natl. Acad. Sci. USA*, 1991, vol. 88, 10591 [0069]
- **SARVER et al.** *Science*, 1990, vol. 247, 1222 [0069]
- **SIOUD et al.** *J. Mol. Biol.*, 1992, vol. 223, 831 [0069]
- **COUZIN.** *Science*, 2008, vol. 319, 1782-4 [0070]
- **CHEN et al.** *Genet*, 2006, vol. 38, 228-33 [0070]
- **VAN ROOIJ et al.** *Trends Genet.*, 2008, vol. 24, 159-66 [0070]
- **BROWN et al.** *Blood*, 2007, vol. 110, 4144-52 [0070]
- **SHARP et al.** *Genes Dev*, 2001, vol. 15, 485-490 [0077]
- **HAMMOND et al.** *Nature Rev. Gen.*, 2001, vol. 2, 110-119 [0077]
- **ELBASHIR et al.** *Nature*, 2001, vol. 411, 494-8 [0077] [0078]
- **GIL et al.** *Apoptosis*, 2000, vol. 5, 107 [0078]
- **CAPLEN et al.** *Proc. Nat. Acad. Sci. USA*, 2001, vol. 98, 9742 [0078]
- **PADDISON et al.** *Proc. Nat. Acad. Sci. USA*, 2002, vol. 99, 1443-1448 [0079]
- **SHINAGAWA et al.** *Genes Dev*, 2003, vol. 17, 1340 [0082]
- **XIA et al.** *Nature Biotech.*, 2002, vol. 20, 1006 [0082]
- **MIYAMURA et al.** *Proc. Nat. Acad. Sci. USA*, 1994, vol. 91, 8507 [0092]
- **S.A. ROSENBERG.** *Immunity*, 1999, vol. 10, 281 [0094]
- **KAWAKAMI et al.** *Proc. Natl. Acad. Sci. USA*, 1994, vol. 91, 3515 [0094]
- **KAWAKAMI et al.** *J. Exp. Med.*, 1994, vol. 180, 347 [0094]
- **KAWAKAMI et al.** *Cancer Res.*, 1994, vol. 54, 3124 [0094]
- **COULIE et al.** *J. Exp. Med.*, 1991, vol. 180, 35 [0094]
- **WICK et al.** *J. Cutan. Pathol.*, 1988, vol. 4, 201 [0094]
- **VAN DER BRUGGEN et al.** *Science*, 1991, vol. 254, 1643 [0094]
- **BRICHARD et al.** *J. Exp. Med.*, 1993, vol. 178, 489 [0094]
- **LEVINE.** *Ann. Rev. Biochem.*, 1993, vol. 62, 623 [0094]
- **ROSENBERG.** *Annu. Rev. Med.*, 1996, vol. 47, 481-91 [0094]
- **SAMBROOK et al.** *Molecular Cloning, A Laboratory Manual.* Cold Spring Harbor Laboratory, 1989 [0106]
- **ALTSCHUL et al.** *Nucleic Acids Res.*, 1997, vol. 25 (17), 3389-3402 [0108] [0109]
- *Sequence Analysis Software Package of the Genetics Computer Group.* University of Wisconsin Biotechnology Center, 53705 [0109]
- **PALOMBO et al.** *J. Virol.*, 1998, vol. 72, 5025 [0121]
- **FERRARI et al.** *Nature Med.*, 1997, vol. 3, 1295 [0123]
- **MARGOLSKI.** *Curr. Top. Microbiol. Immun.*, 1992, vol. 158, 67 [0128]
- **CONWAY et al.** *Gene Therapy*, 1999, vol. 6, 986 [0131]
- **URABE et al.** *Human Gene Therapy*, 2002, vol. 13, 1935-43 [0132]
- **ZOLOTUKHIN et al.** *Gene Therapy*, 1999, vol. 6, 973 [0134]
- **WALKER et al.** *Mol. Immunol.*, 1989, vol. 26, 403-11 [0137]
- **HUSE et al.** *Science*, 1989, vol. 254, 1275-1281 [0138]
- **KOHLER ; MILSTEIN.** *Nature*, 1975, vol. 265, 495-97 [0140]
- **W. HUSE.** *Science*, 1989, vol. 246, 1275-81 [0140]
- *Diagnostic and Statistical Manual of Mental Disorders.* American Psychiatric Association, 1994 [0149]
- **HERBERT B. HERSCOWITZ.** *Immunophysiology: Cell Function and Cellular Interactions in Antibody Formation*, in IMMUNOLOGY: BASIC PROCESSES. 1985, vol. 117 [0167]
- **ARRUDA et al.** *Blood*, 2005, vol. 105, 3458-3464 [0198]
- *Pharm. Res.*, 1986, vol. 3, 318 [0215]
- **LI et al.** *J. Virol.*, 2012, vol. 86, 7752-7759 [0218]
- **PULICHERLA et al.** *Mol. Ther.*, 2011, vol. 19, 1070-1078 [0218]
- **BOWLES et al.** *Mol. Ther.*, 2012, vol. 20, 443-455 [0218]
- **ASOKAN et al.** *Mol. Ther.*, 2012, vol. 20, 699-708 [0218]
- **ASOKAN et al.** *Nature Biotechnol.*, 2010, vol. 28, 79-82 [0218]